Integer (ITGR) 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 27, 2013	Nov. 05, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GREATBATCH, INC.	'
Entity Central Index Key	'0001114483	'
Document Type	'10-Q	'
Document Period End Date	27-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--01-03	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	24,135,656

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$4,973	$20,284
Accounts receivable, net of allowance for doubtful accounts	130,966	120,923
Inventories	122,823	106,612
Refundable income taxes	566	0
Deferred income taxes	8,077	7,678
Prepaid expenses and other current assets	8,028	12,636
Total current assets	275,433	268,133
Property, plant and equipment, net	147,431	150,893
Amortizing intangible assets, net	77,518	87,345
Indefinite-lived intangible assets	20,402	20,828
Goodwill	346,614	349,035
Deferred income taxes	2,762	2,534
Other assets	14,551	11,107
Total assets	884,711	889,875
Current liabilities:	'	'
Accounts payable	36,478	45,274
Income taxes payable	11,177	94
Deferred income taxes	881	874
Accrued expenses	43,207	45,515
Total current liabilities	91,743	91,757
Long-term debt	210,000	225,414
Deferred income taxes	51,732	82,462
Other long-term liabilities	6,779	9,382
Total liabilities	360,254	409,015
Stockholders' equity:	'	'
Preferred stock	0	0
Common stock	24	24
Additional paid-in capital	336,491	320,618
Treasury stock, at cost	-593	-452
Retained earnings	174,209	147,723
Accumulated other comprehensive income (loss)	14,326	12,947
Total stockholders' equity	524,457	480,860
Total liabilities and stockholders' equity	$884,711	$889,875

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Allowance for doubtful accounts	$2,000,000	$2,400,000
Stockholders' equity:	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	24,141,395	23,731,570
Common stock, shares outstanding	24,119,390	23,711,838
Treasury stock, shares	22,005	19,732

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Condensed Consolidated Statements of Operations and Comprehensive Income [Abstract]	'	'	'	'
Sales	$167,730	$161,340	$487,326	$486,991
Cost of sales	111,853	110,386	325,398	337,216
Gross profit	55,877	50,954	161,928	149,775
Operating expenses:	'	'	'	'
Selling, general and administrative expenses	21,569	20,274	63,909	60,053
Research, development and engineering costs, net	13,806	13,240	38,983	41,325
Other operating (income) expense, net	3,500	15,313	10,560	23,981
Total operating expenses	38,875	48,827	113,452	125,359
Operating income (loss)	17,002	2,127	48,476	24,416
Interest expense	1,515	4,401	9,948	13,175
Other (income) expense	-57	-102	907	424
Income before provision for income taxes	15,544	-2,172	37,621	10,817
Provision for income taxes	4,473	5,389	11,135	10,060
Net income (loss)	11,071	-7,561	26,486	757
Earnings per share:	'	'	'	'
Basic	$0.46	($0.32)	$1.11	$0.03
Diluted	$0.44	($0.32)	$1.06	$0.03
Weighted average shares outstanding:	'	'	'	'
Basic	24,047	23,646	23,904	23,559
Diluted	25,188	23,646	25,017	23,924
Comprehensive income (loss):	'	'	'	'
Net income (loss)	11,071	-7,561	26,486	757
Foreign currency translation gain (loss)	3,579	1,005	1,147	-522
Net change in cash flow hedges, net of tax	-403	399	-365	924
Defined benefit plan liability adjustment, net of tax	0	0	597	0
Total other comprehensive income (loss)	3,176	1,404	1,379	402
Comprehensive income (loss)	$14,247	($6,157)	$27,865	$1,159

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012
Cash flows from operating activities:	'	'
Net income (loss)	$26,486	$757
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	26,658	34,070
Debt related amortization included in interest expense	6,171	9,008
Stock-based compensation	11,413	9,007
Other non-cash (gains) losses	184	2,950
Deferred income taxes	-31,197	3,004
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable	-9,901	-22,795
Inventories	-15,999	-4,765
Prepaid expenses and other current assets	1,010	1,380
Accounts payable	-7,220	3,257
Accrued expenses	-1,732	-314
Income taxes payable	10,202	3,985
Net cash provided by (used in) operating activities	16,075	39,544
Cash flows from investing activities:	'	'
Acquisition of property, plant and equipment	-14,953	-33,645
Proceeds from sale of orthopaedic product lines	3,228	0
Net proceeds from sale (purchase) of cost and equity method investments, net	-1,928	-1,653
Acquisitions, net of cash acquired	0	-17,224
Other investing activities	-194	95
Net cash provided by (used in) investing activities	-13,847	-52,427
Cash flows from financing activities:	'	'
Principal payments of long-term debt	-445,782	-24,000
Proceeds from issuance of long-term debt	425,000	10,000
Issuance of common stock	6,213	1,056
Payment of debt issuance costs	-2,697	0
Other financing activities	-327	-12
Net cash provided by (used in) financing activities	-17,593	-12,956
Effect of foreign currency exchange rates on cash and cash equivalents	54	174
Net increase (decrease) in cash and cash equivalents	-15,311	-25,665
Cash and cash equivalents, beginning of period	20,284	36,508
Cash and cash equivalents, end of period	$4,973	$10,843

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
In Thousands
Balance at Dec. 28, 2012	$480,860	$24	$320,618	($452)	$147,723	$12,947
Balance, shares at Dec. 28, 2012	'	23,732	'	-20	'	'
Stock-based compensation	7,742	'	7,742	'	'	'
Net shares issued under stock incentive plans, shares	'	318	'	-2	'	'
Net shares issued under stock incentive plans	5,513	'	5,654	-141	'	'
Income tax liability from stock options, restricted stock and restricted stock units	0	'	0	'	'	'
Shares contributed to 401(k), shares	'	91	'	'	'	'
Shares contrbuted to 401(k)	2,477	'	2,477	'	'	'
Net income (loss)	26,486	'	'	'	26,486	'
Total other comprehensive income (loss)	1,379	'	'	'	'	1,379
Balance at Sep. 27, 2013	$524,457	$24	$336,491	($593)	$174,209	$14,326
Balance, shares at Sep. 27, 2013	'	24,141	'	-22	'	'

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 27, 2013
Basis of Presentation [Abstract]	'
BASIS OF PRESENTATION	'
	1. BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The December 28, 2012 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 28, 2012. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. The third quarter and year-to-date periods of 2013 and 2012 each contained 13 weeks and 39 weeks, respectively, and ended on September 27, and September 28, respectively.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 27, 2013
Business Combinations [Abstract]	'
ACQUISITIONS	'
	2. ACQUISITIONS
	NeuroNexus Technologies, Inc.
	On February 16, 2012, the Company purchased all of the outstanding common stock of NeuroNexus Technologies, Inc. (“NeuroNexus”) headquartered in Ann Arbor, MI. NeuroNexus is an active implantable medical device design firm specializing in developing and commercializing neural interface technology, components and systems for neuroscience and clinical markets. NeuroNexus has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of neural interface devices across a wide range of applications including neuromodulation, sensing, optical stimulation and targeted drug delivery. The aggregate purchase price of NeuroNexus was $13.2 million. Total assets acquired from NeuroNexus were $14.6 million, of which $2.9 million were amortizing intangible assets and $8.9 million was allocated to goodwill.
	This transaction was accounted for under the acquisition method of accounting. Accordingly, the operating results of NeuroNexus were included in the Company's Implantable Medical segment from the date of acquisition and the purchase price was allocated to the assets acquired and liabilities assumed based on their fair values as of the close of the acquisition, with the amount exceeding the fair value of net assets acquired being recorded as goodwill. The purchase price of NeuroNexus consisted of cash payments of $11.7 million and potential future payments of up to an additional $2 million. These future payments are contingent upon the achievement of certain financial and development-based milestones and had an estimated fair value of $1.5 million as of the acquisition date. The valuation of the assets acquired and liabilities assumed from NeuroNexus was finalized during the first quarter of 2013 and did not result in a material adjustment to the original valuation of net assets acquired, including goodwill.
	Pro Forma Results (Unaudited)
	The following unaudited pro forma information presents the consolidated results of operations of the Company and NeuroNexus as if that acquisition occurred as of the beginning of fiscal year 2012 (in thousands, except per share amounts):
				Three Months Ended				Nine Months Ended
				September 27,		September 28,		September 27,		September 28,
				2013		2012		2013		2012
		Sales		$	167,730	$	161,340	$	487,326	$	487,431
		Net income (loss)			11,071		-7,561		26,486		583
		Earnings (loss) per share:
			Basic	$	0.46	$	-0.32	$	1.11	$	0.02
			Diluted	$	0.44	$	-0.32	$	1.06	$	0.02
	The unaudited pro forma information presents the combined operating results of Greatbatch and NeuroNexus, with the results prior to the acquisition date adjusted to include the pro forma impact of the amortization of acquired intangible assets based on the purchase price allocations, the adjustment to interest expense reflecting the amount borrowed in connection with the acquisition at Greatbatch's interest rate, and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The unaudited pro forma consolidated basic and diluted earnings (loss) per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch.
	The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain cost savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	9 Months Ended
	Sep. 27, 2013
Supplemental Cash Flow Information [Abstract]	'
SUPPLEMENTAL CASH FLOW INFORMATION	'
	3. SUPPLEMENTAL CASH FLOW INFORMATION
					Nine Months Ended
						September 27,		September 28,
		(in thousands)				2013		2012
		Noncash investing and financing activities:
			Common stock contributed to 401(k) Plan		$	2,477	$	4,793
			Property, plant and equipment purchases included
				in accounts payable		711		4,611
		Cash paid during the period for:
			Interest		$	4,388	$	3,250
			Income taxes			31,755		2,923
		Acquisition of noncash assets			$	-	$	14,396
		Liabilities assumed				-		1,244

Inventories

Inventories	9 Months Ended
	Sep. 27, 2013
Inventories [Abstract]	'
INVENTORIES	'
	4. INVENTORIES
		Inventories are comprised of the following (in thousands):
			As of
				September 27,		December 28,
				2013		2012
		Raw materials	$	67,515	$	58,204
		Work-in-process		38,321		30,022
		Finished goods		16,987		18,386
		Total	$	122,823	$	106,612

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 27, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	5. INTANGIBLE ASSETS
		Amortizing intangible assets are comprised of the following (in thousands):
		At	27-Sep-13		Gross Carrying Amount			Accumulated Amortization			Foreign Currency Translation			Net Carrying Amount
		Technology and patents		$	95,576		$	-68,427		$	3,129		$	30,278
		Customer lists			68,257			-22,076			207			46,388
		Other			4,434			-4,385			803			852
		Total amortizing intangible assets		$	168,267		$	-94,888		$	4,139		$	77,518
		At	28-Dec-12
		Technology and patents		$	95,576		$	-61,659		$	1,932		$	35,849
		Customer lists			68,257			-18,929			1,270			50,598
		Other			4,434			-4,341			805			898
		Total amortizing intangible assets		$	168,267		$	-84,929		$	4,007		$	87,345
		Aggregate intangible asset amortization expense is comprised of the following (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,			September 28,
			2013			2012			2013			2012
		Cost of sales	$	1,668		$	1,863		$	5,207		$	5,658
		Selling, general and administrative expenses		1,446			1,573			4,343			4,713
		Research, development and engineering costs, net		137			136			409			409
		Total intangible asset amortization expense	$	3,251		$	3,572		$	9,959		$	10,780
		Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands):
				Estimated
				Amortization
				Expense
		Remainder of	2013	$	3,207
		2014			13,437
		2015			12,386
		2016			10,092
		2017			8,969
		Thereafter			29,427
		Total estimated amortization expense		$	77,518
		Indefinite-lived intangible assets are comprised of the following (in thousands):
					Trademarks and Tradenames			IPR&D			Total
		At	28-Dec-12	$	20,288		$	540		$	20,828
		Indefinite-lived asset write-off			-			-426			-426
		At	27-Sep-13	$	20,288		$	114		$	20,402
		The change in goodwill is as follows (in thousands):
					Implantable Medical			Electrochem			Total
		At	28-Dec-12	$	307,201		$	41,834		$	349,035
		Goodwill disposed (Note 9)			-2,771			-			-2,771
		Foreign currency translation			350			-			350
		At	27-Sep-13	$	304,780		$	41,834		$	346,614

Debt

Debt	9 Months Ended
	Sep. 27, 2013
Debt Disclosure [Abstract]	'
DEBT	'
	6. DEBT
		Long-term debt is comprised of the following (in thousands):
				As of
					September 27,			December 28,
					2013			2012
		Revolving line of credit		$	10,000		$	33,000
		Variable rate term loan			200,000			-
		2.25% convertible subordinated notes			-			197,782
		Unamortized discount			-			-5,368
			Total long-term debt	$	210,000		$	225,414
	Credit Facility –In September 2013, the Company amended and extended its credit facility (the “Credit Facility”). The new Credit Facility provides a $300 million revolving credit facility (the “Revolving Credit Facility”), a $200 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The Credit Facility can be increased by $200 million upon the Company's request and approval by the lenders. The Revolving Credit Facility has a maturity date of September 20, 2018, which may be extended to September 20, 2019 upon notice by the Company and subject to certain conditions. The principal of the Term Loan is payable in quarterly installments as specified in the Credit Facility until its maturity date of September 20, 2019 when the unpaid balance is due in full.
	The Credit Facility is secured by the Company's non-realty assets including cash, accounts receivable and inventories. Interest rates on the revolving and term loans under the Credit Facility are, at the Company's option either at: (i) the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company's total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranges between 1.375% and 2.75%, based on the Company's total leverage ratio. Loans under the swingline subfacility will bear interest at the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company's total leverage ratio. The Company is also required to pay a commitment fee, which varies between 0.175% and 0.25% depending on the Company's total leverage ratio.
	The Credit Facility contains limitations on the incurrence of indebtedness, liens and licensing of intellectual property, investments and certain payments. The Credit Facility permits the Company to engage in the following activities up to an aggregate amount of $300 million: 1) engage in permitted acquisitions in the aggregate not to exceed $250 million; 2) make other investments in the aggregate not to exceed $100 million; 3) make stock repurchases and declare dividends not to exceed $150 million in the aggregate; and 4) make investments in foreign subsidiaries not to exceed $20 million in the aggregate. At any time that the total leverage ratio of the Company for the two most recently ended fiscal quarters is less than 2.75 to 1.0, the Company may make an election to reset each of the amounts specified above. Additionally, these limitations can be waived upon the Company's request and approval of a majority of the lenders. As of September 27, 2013, the Company had available to it 100% of the above limits except for the aggregate limit and other investments limit which are now $299 million and $99 million, respectively.
	The Credit Facility requires the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.5 to 1.0 and a total leverage ratio not greater than 4.25 to 1.0 after January 2, 2016. The calculation of adjusted EBITDA and total leverage ratio excludes non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of September 27, 2013, the Company was in compliance with all covenants under the Credit Facility.
	The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable.
	As of September 27, 2013, the weighted average interest rate on borrowings under the Credit Facility, which does not take into account the impact of the Company's interest rate swap, was 1.81%. As of September 27, 2013, the Company had $290 million of borrowing capacity available under the Credit Facility. This borrowing capacity may vary from period to period based upon the debt and EBITDA levels of the Company, which impacts the covenant calculations described above.
	Interest Rate Swap – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility. The variable rate received on the interest rate swaps and the variable rate paid on the debt have the same rate of interest, excluding the credit spread, and resets and pays interest on the same date. During 2012, the Company entered into a three-year $150 million interest rate swap, which amortizes $50 million per year. This swap was entered into in order to hedge against potential changes in cash flows on the outstanding Credit Facility borrowings, which are also indexed to the one-month LIBOR rate. This swap is being accounted for as a cash flow hedge. Information regarding the Company's outstanding interest rate swap as of September 27, 2013 is as follows (dollars in thousands):
													Current		Fair
											Pay		Receive		Value		Balance
			Type of		Notional			Start		End	Fixed		Floating		Sept. 27,		Sheet
	Instrument		Hedge		Amount			Date		Date	Rate		Rate		2013		Location
	Interest rate swap		Cash flow		$	150,000		13-Feb		16-Feb	0.57%			0.18%	$	-400	Other Long-Term Liabilities
	The estimated fair value of the interest rate swap agreement represents the amount the Company expects to receive (pay) to terminate the contract. No portion of the change in fair value of the Company's interest rate swap during the nine months ended September 27, 2013 was considered ineffective. The amount recorded as Interest Expense during the three and nine months ended September 27, 2013 related to the Company's interest rate swap was $0.1 million and $0.3 million, respectively.
	Convertible Subordinated Notes – In March 2007, the Company issued $197.8 million of convertible subordinated notes (“CSN”) at a 5% discount. CSN accrued interest at 2.25% per annum. The effective interest rate of CSN, which took into consideration the amortization of the discount and deferred fees related to the issuance of these notes, was 8.5%. On February 20, 2013, the Company redeemed all outstanding CSN.
		The contractual interest and discount amortization for CSN were as follows (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,		September 28,
			2013			2012			2013		2012
		Contractual interest	$	-		$	1,113		$	634	$	3,338
		Discount amortization		-			2,781			5,368		8,205
	The expected future minimum principal payments under the Credit Facility as of September 27, 2013 is as follows (in thousands):
		Remainder of 2013				$	2,500
		2014					10,000
		2015					11,250
		2016					16,250
		2017					20,000
		Thereafter					150,000
		Total				$	210,000
	The Company has the ability and intent to use availability under the Revolving Credit Facility to fund principal payments on the Term Loan.
	Deferred Financing Fees - The change in deferred financing fees is as follows (in thousands):
		At	28-Dec-12	$	2,056
		Financing costs deferred			2,697
		Write-off during the period			-156
		Amortization during the period			-648
		At	27-Sep-13	$	3,949

Defined_Benefit_Plans

Defined Benefit Plans	9 Months Ended
	Sep. 27, 2013
Defined Benefit Plans [Abstract]	'
DEFINED BENEFIT PLANS	'
	7. DEFINED BENEFIT PLANS
	The Company is required to provide its employees located in Switzerland, Mexico and France certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit plan provided to employees located in Switzerland is a funded contributory plan while the plans that provide benefits to employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees.
	During 2012, the Company transferred manufacturing and development operations performed at its facilities in Switzerland into other existing facilities. As a result, the Company curtailed its defined benefit plan provided to employees at those Swiss facilities during the third quarter of 2012. In accordance with ASC 715, the gain recognized in connection with this curtailment is realized as the related employees are terminated. As nearly all of the Swiss pension liability is expected to be paid in 2013, the Company moved all Swiss pension plan assets into cash accounts during 2012. Swiss plan assets are expected to be sufficient to cover plan liabilities. During 2013, the Company settled approximately $7.7 million of its defined benefit obligation.
		The change in net defined benefit plan liability is as follows (in thousands):
		At	28-Dec-12	$	3,946
		Service cost			227
		Interest cost			144
		Curtailment			-1,581
		Actuarial gain			-171
		Benefit payments			-125
		Foreign currency translation			14
		At	27-Sep-13	$	2,454
		Amounts recognized in Accumulated Other Comprehensive Income are as follows (in thousands):
							Nine Months Ended
							27-Sep-13
		Net gain occurring during the period					$	-171
		Amortization of losses						-581
		Prior service cost						155
		Pre-tax adjustment						-597
		Taxes						-
		Net gain					$	-597
		Net defined benefit cost (income) is comprised of the following (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,		September 28,
			2013			2012			2013		2012
		Service cost	$	76		$	272		$	227	$	835
		Interest cost		41			98			144		305
		Curtailment gain (Other Operating Expenses, Net)		-			-			-1,150		-
		Amortization of net loss		-			30			-		92
		Expected return on plan assets		-			-103			-		-318
		Net defined benefit (income) cost	$	117		$	297		$	-779	$	914

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 27, 2013
Stock-Based Compensation [Abstract]	'
STOCK-BASED COMPENSATION	'
	8. STOCK-BASED COMPENSATION
		The components and classification of stock-based compensation expense were as follows (in thousands):
			Three Months Ended					Nine Months Ended
			September 27,			September 28,		September 27,		September 28,
				2013			2012		2013		2012
		Stock options	$	1,374		$	671	$	2,784	$	2,038
		Restricted stock and units		2,013			1,523		4,958		4,559
		401(k) stock contribution		679			1,280		3,671		2,410
		Total stock-based compensation expense	$	4,066		$	3,474	$	11,413	$	9,007
		Cost of sales	$	1,117		$	1,119	$	3,246	$	2,486
		Selling, general and administrative		1,598			2,006		6,052		5,732
		Research, development and engineering		215			349		979		789
		2013 operating unit realignment modification expense - Other Operating Expenses, Net (Note 9)		1,136			-		1,136		-
		Total stock-based compensation expense	$	4,066		$	3,474	$	11,413	$	9,007
		The weighted average fair value and assumptions used to value options granted are as follows:
			Nine Months Ended
				September 27,			September 28,
				2013			2012
		Weighted average fair value	$	8.38		$	8.2
		Risk-free interest rate		0.73%			0.83%
		Expected volatility		39%			40%
		Expected life (in years)		5			5
		Expected dividend yield		0%			0%
		The following table summarizes time-vested stock option activity:
							Number of Time-Vested Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value (In Millions)
		Outstanding at			28-Dec-12		1,775,847	$	23.17
			Granted				372,676		23.33
			Exercised				-215,200		22.87
			Forfeited or expired				-69,467		26.2
		Outstanding at			27-Sep-13		1,863,856	$	23.13		6.2	$	19.9
		Exercisable at			27-Sep-13		1,287,345	$	23.17		5	$	13.7
		The following table summarizes performance-vested stock option activity:
							Number of Performance-Vested Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value (In Millions)
		Outstanding at			28-Dec-12		284,925	$	23.26
			Granted				0		0
			Exercised				-55,571		23.21
			Forfeited or expired				-		-
		Outstanding at			27-Sep-13		229,354	$	23.27		3.6	$	2.4
		Exercisable at			27-Sep-13		229,354	$	23.27		3.6	$	2.4
		The following table summarizes time-vested restricted stock and unit activity:
							Time-Vested Activity		Weighted Average Fair Value
		Nonvested at			28-Dec-12		80,269	$	23.48
			Granted				63,022		25.85
			Vested				-30,592		22.46
			Forfeited				-4,463		21.65
		Nonvested at			27-Sep-13		108,236	$	25.23
		The following table summarizes performance-vested restricted stock and unit activity:
							Performance-Vested Activity		Weighted Average Fair Value
		Nonvested at			28-Dec-12		782,446	$	16.02
			Granted				318,169		15.86
			Vested				-49,139		14.68
			Forfeited				-240,312		14.94
		Nonvested at			27-Sep-13		811,164	$	16.36

Other_Operating_Income_Expense

Other Operating (Income) Expense, Net	9 Months Ended
	Sep. 27, 2013
Other Operating (Income) Expense, Net [Abstract]	'
OTHER OPERATING (INCOME) EXPENSE NET	'
	9. OTHER OPERATING EXPENSES, NET
		Other Operating Expenses, Net is comprised of the following (in thousands):
			Three Months Ended				Nine Months Ended
			September 27,		September 28,		September 27,		September 28,
				2013		2012		2013		2012
		2013 operating unit realignment	$	2,214	$	-	$	3,066	$	-
		Orthopaedic facility optimization		1,420		12,452		6,723		14,774
		Medical device facility optimization		52		388		282		1,282
		ERP system upgrade		-121		1,938		264		4,745
		Acquisition and integration (income) costs		-522		232		-340		1,287
		Asset dispositions, severance and other		457		303		565		1,893
			$	3,500	$	15,313	$	10,560	$	23,981
	2013 operating unit realignment. In June 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its Implantable Medical and Electrochem segments were combined into one sales and marketing and one operations group serving the entire Company. Total restructuring charges expected to be incurred in connection with this realignment is between $6.2 million and $7.0 million, of which $3.1 million has been incurred to date. Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
	Severance and retention: $5.0 million - $5.2 million; and
	Other: $1.2 million – $1.8 million.
	Other costs primarily consist of relocation, recruitment and travel expenditures.
	The change in accrued liabilities related to the 2013 operating unit realignment is as follows (in thousands):
				Severance and Retention		Other		Total
	At	28-Dec-12	$	0	$	0	$	0
	Restructuring charges			2,153		913		3,066
	Non-cash settlement (modification expense - Note 8)			-1,136		-		-1,136
	Cash payments			-391		-463		-854
	At	27-Sep-13	$	626	$	450	$	1,076
	Orthopaedic facility optimization. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011.
	In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred the manufacturing operations being performed at its Columbia City, IN facility into this new facility. This initiative was completed in 2012.
	During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, in 2012, the Company entered into an agreement to sell assets related to certain non-core Swiss orthopaedic product lines to an independent third party including inventory, machinery, equipment, customer lists and technology related to these product lines. As these product lines were considered a business, goodwill was allocated to the transaction (See Note 5). As these product lines did not have cash flows that were clearly distinguishable, both operationally and for financial reporting purposes, from the rest of the Company, they were not considered discontinued operations. This transaction closed in the first quarter of 2013 and no additional loss on sale was recognized. During 2013, the Company received payments totaling $3.2 million in connection with this transaction and the third party assumed $2.4 million of severance liabilities.
	The total capital investment expected for these initiatives is between $25 million and $30 million, of which $22.0 million has been expended to date. Total expense expected to be incurred for these initiatives is between $40 million and $41 million, of which $39.9 million has been incurred to date. All expenses will be recorded within the Implantable Medical segment and are expected to include the following:
	Severance and retention: approximately $11 million;
	Accelerated depreciation and asset write-offs: approximately $15 million; and
	Other: $14 million - $15 million.
	Other costs include production inefficiencies, moving, revalidation, personnel, training and travel costs associated with these consolidation projects.
	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands):
			Severance and Retention		Accelerated Depreciation/Asset Write-offs		Other		Total
	At	28-Dec-12	$	9,567	$	-	$	-	$	9,567
	Restructuring charges			544		192		5,987		6,723
	Write-offs			-		-192		-		-192
	Liability assumed by third party			-2,398		-		-		-2,398
	Cash payments			-6,978		-		-5,622		-12,600
	At	27-Sep-13	$	735	$	-	$	365	$	1,100
	Medical device facility optimization. Near the end of 2011, the Company initiated plans to upgrade and expand its manufacturing infrastructure in order to support its medical device strategy. This includes the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives are expected to be completed over the next year. Total capital investment under these initiatives is expected to be between $15 million and $20 million of which approximately $12.4 million has been expended to date. Total expenses expected to be incurred on these projects is between $2.0 million and $3.0 million, of which $1.8 million has been incurred to date. All expenses will be recorded within the Implantable Medical segment and are expected to include the following:
	Production inefficiencies, moving and revalidation: $0.5 million - $1.0 million;
	Personnel: $1.0 million - $1.5 million; and
	Other: approximately $1.0 million.
	The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands):
				Production Inefficiencies, Moving and Revalidation		Personnel		Other		Total
	At	28-Dec-12	$	0	$	0	$	0	$	0
	Restructuring charges			19		2		261		282
	Cash payments			-19		-2		-261		-282
	At	27-Sep-13	$	0	$	0	$	0	$	0
	ERP system upgrade. In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative is expected to be completed over the next six months. Total capital investment under this initiative is expected to be between $4.5 million to $5 million of which approximately $4.3 million has been expended to date. Total expenses expected to be incurred on this initiative is between $6 million to $7 million, of which $5.3 million has been incurred to date. Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
	Training and consulting costs: $4 million - $4.5 million; and
	Accelerated depreciation and asset write-offs: $2 million – $2.5 million.
	The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands):
				Training & Consulting Costs		Accelerated Depreciation/ Asset Write-offs		Total
	At	28-Dec-12	$	169	$	0	$	169
	Charges			264		-		264
	Cash payments			-433		0		-433
	At	27-Sep-13	$	0	$	0	$	0
	Acquisition and integration (income) costs. During 2013 and 2012, the Company incurred costs (income) related to the integration of Micro Power Electronics, Inc. and NeuroNexus, which were acquired in December 2011 and February 2012, respectively. These expenses were primarily for retention bonuses, travel costs in connection with integration efforts, training, severance, and the change in fair value of the contingent consideration recorded in connection with these acquisitions.
	Asset dispositions, severance and other. During 2013 and 2012, the Company recorded (gains) losses in connection with various asset disposals and/or write-down's. Additionally, during the second quarter of 2012, the Company incurred $1.2 million of costs related to the relocation of its global headquarters to Frisco, Texas.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 27, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	10. INCOME TAXES
	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
	As of September 27, 2013, the balance of unrecognized tax benefits is approximately $1.4 million. It is reasonably possible that a reduction of up to $0.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $1.2 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.
	As a result of the repayment of CSN during the first quarter of 2013, the Company reclassified $30.4 million of Long-Term Deferred Income Taxes to Income Taxes Payable of which approximately $8.0 million was paid in the third quarter of 2013 and $19.6 million was paid in the first nine months of 2013.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 27, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	11. COMMITMENTS AND CONTINGENCIES
	Litigation – The Company is a party to various legal actions arising in the normal course of business. While the Company does not believe that the ultimate resolution of any such pending actions will have a material effect on its results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties. If an unfavorable ruling were to occur, there exists the possibility of a material impact in the period in which the ruling occurs.
	During 2012, Electrochem and several other unaffiliated parties were named as defendants in a personal injury and wrongful death action filed in the 113th Judicial District Court of Harris County, Texas. The complaint seeks damages alleging marketing defects and failure to warn, negligence and gross negligence relating to a product Electrochem manufactured and sold to a customer, one of the other named defendants, which, in turn, incorporated the Electrochem product into its own product which it sold to its customer, another named defendant. The cost of defense in this matter is the responsibility of Electrochem's customer. Electrochem also has product liability insurance coverage. Electrochem believes that it has meritorious defenses and it intends to vigorously defend the matter. Given the early stages of this action, the amount of loss or range of possible loss cannot be reasonably estimated at this time.
	Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in aggregate product warranty liability is as follows (in thousands):
		At	28-Dec-12	$	2,626
		Additions to warranty reserve			1,372
		Warranty claims paid			-123
		At	27-Sep-13	$	3,875
	Contractual Obligations – Contractual obligations are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum obligations; fixed or minimum price provisions; and the approximate timing of the transaction. The Company's contractual obligations are normally fulfilled within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable without penalty. As of September 27, 2013, the total contractual obligations of the Company are approximately $24.1 million and will primarily be funded by existing cash and cash equivalents, cash flow from operations, or the Credit Facility. The Company also enters into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty.
	Operating Leases – The Company is a party to various operating lease agreements for buildings, equipment and software. Estimated future operating lease expense is as follows (in thousands):
		Remainder of	2013	$	1,400
		2014			5,123
		2015			4,522
		2016			3,826
		2017			1,424
		Thereafter			1,933
		Total estimated operating lease expense		$	18,228
	Foreign Currency Contracts - The Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with the operations at its Tijuana, Mexico facility. The impact to the Company's results of operations from these forward contracts was as follows (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,		September 28,
			2013			2012			2013		2012
		Increase (reduction) in cost of sales	$	-346		$	11		$	-908	$	-8
		Ineffective portion of change in fair value		0			0			0		0
	Instrument		Type of Hedge			Aggregate Notional Amount		Start Date		End Date	$/Peso		Fair Value	Balance Sheet Location
	FX Contract		Cash flow		$	1,500		13-Jan		13-Dec	0.0727	$	59	Current Assets
	FX Contract		Cash flow			1,500		13-Jan		13-Dec	0.0693		138	Current Assets
	FX Contract		Cash flow			7,700		14-Jan		14-Dec	0.0767		-239	Current Assets/ Other Long-Term Liabilities
	Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The risk to the Company is being limited through the use of stop loss insurance, which has specific stop loss coverage per associate for claims in the year exceeding $225 thousand per associate with no annual maximum aggregate stop loss coverage. As of September 27, 2013, the Company has $1.9 million accrued related to the self-insurance of its medical plan, which is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet, and is primarily based upon claim history.

Earnings_Per_Share_Eps

Earnings Per Share (Eps)	9 Months Ended
	Sep. 27, 2013
EARNINGS PER SHARE (EPS) [Abstract]	'
EARNINGS PER SHARE (EPS)	'
	12. EARNINGS (LOSS) PER SHARE (“EPS”)
	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
				Three Months Ended					Nine Months Ended
				September 27,		September 28,			September 27,		September 28,
				2013		2012			2013		2012
	Numerator for basic and diluted EPS:
		Net income (loss)		$	11,071	$	-7,561		$	26,486	$	757
	Denominator for basic EPS:
		Weighted average shares outstanding			24,047		23,646			23,904		23,559
	Effect of dilutive securities:
		Stock options, restricted stock and restricted stock units			1,141		-			1,113		365
	Denominator for diluted EPS				25,188		23,646			25,017		23,924
	Basic EPS			$	0.46	$	-0.32		$	1.11	$	0.03
	Diluted EPS			$	0.44	$	-0.32		$	1.06	$	0.03
		The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
					Three Months Ended			Nine Months Ended
					September 27,	September 28,		September 27,		September 28,
					2013	2012		2013		2012
		Time-vested stock options, restricted
			stock and restricted stock units		43,000	2,223,000		59,000		1,237,000
		Performance-vested stock options
			and restricted stock units		27,000	781,000		26,000		692,000
	For the 2013 and 2012 periods, no shares related to CSN were included in the diluted EPS calculations as the average share price of the Company's common stock for those periods did not exceed CSN's conversion price per share.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 27, 2013
Accumulated Other Comprehensive Income Notes [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE INCOME	'
	13. ACCUMULATED OTHER COMPREHENSIVE INCOME
	Accumulated Other Comprehensive Income for the quarter and year to date periods are as follows (in thousands):
	Three Month Period		Defined Benefit Plan Liability		Cash Flow Hedges		Foreign Currency Translation Adjustment		Total Pre-Tax Amount		Tax		Net-of-Tax Amount
	At	28-Jun-13	$	-365	$	178	$	10,999	$	10,812	$	338	$	11,150
	Unrealized loss on cash flow hedges			-		-419		-		-419		147		-272
	Realized gain on foreign currency hedges			-		-346		-		-346		121		-225
	Realized loss on interest rate swap hedges			-		145		-		145		-51		94
	Foreign currency translation gain			-		-		3,579		3,579		0		3,579
	At	27-Sep-13	$	-365	$	-442	$	14,578	$	13,771	$	555	$	14,326
	Nine Month Period		Defined Benefit Plan Liability		Cash Flow Hedges		Foreign Currency Translation Adjustment		Total Pre-Tax Amount		Tax		Net-of-Tax Amount
	At	28-Dec-12	$	-962	$	120	$	13,431	$	12,589	$	358	$	12,947
	Unrealized gain on cash flow hedges			-		2		-		2		-1		1
	Realized gain on foreign currency hedges			-		-908		-		-908		318		-590
	Realized loss on interest rate swap hedges			-		344		-		344		-120		224
	Net defined benefit plan gain (Note 7)			597		-		-		597		-		597
	Foreign currency translation gain			-		-		1,147		1,147		-		1,147
	At	27-Sep-13	$	-365	$	-442	$	14,578	$	13,771	$	555	$	14,326
	The realized (gain) loss relating to the Company's foreign currency and interest rate swap hedges was reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, respectively, in the Condensed Consolidated Statements of Operations.

Fair_Value_Measurements

Fair Value Measurements

9 Months Ended

Sep. 27, 2013

Fair Value Disclosures [Abstract]

'

FAIR VALUE MEASUREMENTS

'

14. FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and accrued contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.

Foreign currency contracts - The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition to the above, the Company receives fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company's estimates. The Company's foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company's foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $0.04 million is expected to be realized within the next twelve months.

Interest rate swap - The fair value of the Company's interest rate swap outstanding at September 27, 2013 was determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition to the above, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company's estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company's interest rate swap will be realized as Interest Expense as interest on the Company's Credit Facility is accrued.

Accrued contingent consideration – In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through Other Operating Expenses, Net. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable milestones.

The fair value of accrued contingent consideration recorded by the Company represents the estimated fair value of the contingent consideration the Company expects to pay to the former shareholders of NeuroNexus based upon the achievement of certain financial and development-based milestones. The fair value of the contingent consideration liability was estimated by discounting to present value, the probability weighted contingent payments expected to be made. The maximum amount of future contingent consideration (undiscounted) that the Company could be required to pay is $2.0 million. The Company's accrued contingent consideration is categorized in Level 3 of the fair value hierarchy. Changes in accrued contingent consideration were as follows (in thousands):

At

28-Dec-12

$

1,530

Fair value adjustments

-430

At

27-Sep-13

$

1,100

The recurring Level 3 fair value measurements of the Company's contingent consideration liability include the following significant unobservable inputs (dollars in thousands):

Fair

Contingent

Value at

Consideration

September 27,

Valuation

Unobservable

Liability

2013

Technique

Inputs

Financial milestones

$

470

Discounted cash flow

Discount rate

12%

Projected year

of payment

2014

Probability weighted payment amount

$

500

Development milestones

630

Discounted cash flow

Discount rate

20%

Projected year

of payment

2016

Probability weighted payment amount

$

1,000

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheet (in thousands):

Fair Value Measurements Using

Quoted

Prices in

Significant

Active Markets

Other

Significant

At

for Identical

Observable

Unobservable

September 27,

Assets

Inputs

Inputs

Description

2013

(Level 1)

(Level 2)

(Level 3)

Assets

Foreign currency contracts (Note 11)

$

37

$

0

$

37

$

0

Liabilities

Interest rate swap (Note 6)

$

400

$

0

$

400

$

0

Foreign currency contracts (Note 11)

79

0

79

0

Accrued contingent consideration

1,100

0

0

1,100

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Fair value standards also apply to certain nonfinancial assets and liabilities that are measured at fair value on a nonrecurring basis. As of September 27, 2013, the fair value of the Company's variable rate Long-Term Debt approximates its carrying value. A summary of the valuation methodologies for the Company's assets and liabilities measured on a nonrecurring basis is as follows:

Long-lived assets - The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that it is more likely than not the long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.

If an indicator is present, potential recoverability is measured by comparing the carrying amount of the long-lived asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group's carrying amount to its fair value, which is determined by using independent appraisals or discounted cash flow models. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, terminal values, operating budgets, long-term strategic plans and remaining useful lives of the asset or asset group. If the carrying value of the long-lived asset or asset group exceeds the fair value, the carrying value is written down to the fair value in the period identified. The Company did not record any impairment charge related to its long-lived assets, other than goodwill and indefinite-lived intangible assets, during the first nine months of 2013. During the first nine months of 2012, the Company recorded an impairment charge to Other Operating Expenses, Net of $0.3 million relating to the write-off of a definite-lived intangible asset.

Goodwill and indefinite-lived intangible assets – The Company assess the impairment of goodwill and other indefinite-lived intangible assets on the last day of each fiscal year, or more frequently if certain indicators are present as described above under long-lived assets. The Company assesses goodwill for impairment by comparing the fair value of its reporting units to their carrying amounts. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Fair values for reporting units are determined based on discounted cash flow models and market multiples. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, terminal values, operating budgets, and long-term strategic plans. The fair value from the discounted cash flow model is then combined, based on certain weightings, with market multiples in order to determine the fair value of the reporting unit. These market multiples include revenue multiples and multiples of earnings before interest, taxes, depreciation and amortization.

Indefinite-lived intangible assets are assessed for impairment by comparing the fair value of the intangible asset to its carrying value. If the carrying value of the indefinite-lived intangible asset exceeds the fair value, the carrying value is written down to the fair value in the period identified. The fair value of indefinite-lived intangible assets is determined by using a discounted cash flow model. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, royalty rates, operating budgets, and long-term strategic plans.

The Company recorded impairment charges in Other Operating Expenses, Net related to its indefinite-lived intangible assets, excluding goodwill, of $0.4 million and $0 during the first nine months of 2013 and 2012, respectively. No impairment loss was recorded for goodwill during the first nine months of 2013 or 2012. Note 5 “Intangible Assets” contains additional information on the Company's intangible assets.

Cost and equity method investments - The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments and are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company's investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other (Income) Expense, Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at September 27, 2013 and December 28, 2012 was $10.6 million and $9.1 million, respectively. The Company recorded losses related to its cost and equity method investments of $0.6 million and $0 during the first nine months of 2013 and 2012, respectively.

Business_Segment_Geographic_an

Business Segment, Geographic and Concentration Risk Information	9 Months Ended
	Sep. 27, 2013
Business Segment, Geographic and Concentration Risk Information [Abstract]	'
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION	'
	15. BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION
	The Company currently operates its business in two reportable segments – Implantable Medical and Electrochem. The Implantable Medical segment is comprised of Greatbatch Medical and QiG Group and designs and manufactures medical devices and components for the cardiac, neuromodulation, vascular and orthopaedic markets. The Implantable Medical segment offers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution, which is facilitated through the QiG Group and leverages the component technology of Greatbatch Medical. The devices designed and developed by the QiG Group are manufactured by Greatbatch Medical. The Implantable Medical segment also offers individual components for implantable medical devices as well as value-added assembly and design engineering services for its component products. Examples of these components include batteries, capacitors, filtered and un-filtered feedthroughs, machined components, enclosures, leads, introducers, catheters, as well as orthopaedic implants, instruments and cases and trays.
	Electrochem is an industry leader in designing and manufacturing total power solutions for critical applications with market-leading OEMs, largely in the portable medical and energy space. Electrochem offers its customers components, consultation, design, development and testing for medical device applications, in high-value markets, including those that support the transition of delivery of health care from clinical to outpatient and home settings, as well as those that enhance the quality of life for an aging population. Examples of these devices include powered surgical tools, automated external defibrillators, portable ultrasound devices, portable oxygen concentrators, and ventilators, among others. Electrochem provides cell and battery pack configurations for rechargeable and non-rechargeable battery power systems, charging and docking stations, and power supplies, for devices where failure is not an option.
	As discussed further in Note 9 “Other Operating Expenses, Net,” in June 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its Implantable Medical and Electrochem segments were combined into one sales and marketing and one operations group serving the entire Company. As a result of this realignment initiative, which includes changing the management and reporting structure, the Company is re-evaluating its operating and reportable segments.
	The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. Segment income also includes a portion of non-segment specific selling, general, and administrative expenses based on allocations appropriate to the expense categories. The remaining unallocated operating and other expenses are primarily administrative corporate headquarters expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant.
	An analysis and reconciliation of the Company's business segment, product line and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on the location to which products are shipped (in thousands):
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
		Sales:			2013			2012		2013		2012
		Implantable Medical
			Cardiac/Neuromodulation		$	86,980		$	80,246	$	242,161	$	235,406
			Orthopaedic			30,079			27,173		92,043		91,079
			Vascular			12,279			13,674		35,152		37,791
				Total Implantable Medical		129,338			121,093		369,356		364,276
		Electrochem
			Portable Medical			19,320			20,219		60,376		59,346
			Energy			13,625			13,054		39,025		41,024
			Other			5,447			6,974		18,569		22,345
				Total Electrochem		38,392			40,247		117,970		122,715
				Total sales	$	167,730		$	161,340	$	487,326	$	486,991
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
					2013			2012		2013		2012
		Segment income from operations:
			Implantable Medical		$	19,074		$	2,744	$	50,057	$	24,252
			Electrochem			2,216			5,350		12,860		16,020
		Total segment income from operations				21,290			8,094		62,917		40,272
		Unallocated operating expenses				-4,288			-5,967		-14,441		-15,856
		Operating income as reported				17,002			2,127		48,476		24,416
		Unallocated other expense				-1,458			-4,299		-10,855		-13,599
		Income (loss) before provision for income taxes			$	15,544		$	-2,172	$	37,621	$	10,817
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
					2013			2012		2013		2012
		Sales by geographic area:
			United States		$	81,736		$	82,522	$	242,304	$	249,306
		Non-Domestic locations:
			Puerto Rico			31,936			31,320		87,592		81,541
			Belgium			14,947			11,346		49,895		41,737
			Rest of world			39,111			36,152		107,535		114,407
				Total sales	$	167,730		$	161,340	$	487,326	$	486,991
		Three customers accounted for a significant portion of the Company’s sales as follows:
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
					2013			2012		2013		2012
		Customer A				21%			19%		20%		19%
		Customer B				16%			18%		16%		15%
		Customer C				11%			10%		13%		10%
			Total			48%			47%		49%		44%
		Long-lived tangible assets by geographic area are as follows (in thousands):
			As of
				September 27,			December 28,
				2013			2012
		United States	$	117,393		$	123,104
		Rest of world		30,038			27,789
		Total	$	147,431		$	150,893

Impact_of_Recently_Issued_Acco

Impact of Recently Issued Accounting Standards	9 Months Ended
	Sep. 27, 2013
Impact of Recently Issued Accounting Standards [Abstract]	'
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS	'
	16. IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS
	In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, Emerging Issues Task Force, American Institute of Certified Public Accountants or other authoritative accounting bodies to determine the potential impact they may have on the Company's Condensed Consolidated Financial Statements. Based upon this review except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company's Condensed Consolidated Financial Statements.
	On February 5, 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income.” This ASU added new disclosure requirements regarding the effect of significant amounts reclassified from each component of accumulated other comprehensive income (“AOCI”) based on its source and the income statement line items affected by the reclassification. This ASU gave companies the flexibility to present the information either in the notes or parenthetically on the face of the financial statements provided that all of the required information is presented in a single location. This ASU was effective prospectively for annual and interim reporting periods beginning after December 15, 2012. This ASU was adopted during the first quarter of 2013 and did not have a material impact on the Company's Condensed Consolidated Financial Statements as it only changed the disclosures surrounding AOCI.
	In July 2012, the FASB issued ASU No. 2012-02, “Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment.” This ASU simplified the guidance for testing the decline in the realizable value (impairment) of indefinite-lived intangible assets other than goodwill. The amendment allowed an organization the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. An organization electing to perform a qualitative assessment is no longer required to calculate the fair value of an indefinite-lived intangible asset unless the organization determines, based on a qualitative assessment, that it is “more likely than not” that the asset is impaired. The amendments in this ASU were effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. This ASU did not have a material impact on the Company's Condensed Consolidated Financial Statements as it only impacted the timing of when the Company was required to perform the two-step impairment test of its indefinite-lived intangible assets other than goodwill.
	In December 2011, the FASB issued ASU No. 2011-11 “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities.” This ASU requires companies to provide expanded disclosures about trading in financial instruments and related derivatives, and creates new disclosure requirements about the nature of an entity's rights of offset and related arrangements associated with its financial instruments and derivative instruments. The disclosure requirements are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods therein, with retrospective application required. This ASU did not have a material impact on the Company's Condensed Consolidated Financial Statements as it only changes the disclosures surrounding the Company's offsetting assets and liabilities.

Accounting_Policies_Policies

Accounting Policies (Policies)	9 Months Ended
	Sep. 27, 2013
Basis of Presentation [Abstract]	'
Interim Basis of Accounting [Policy Text Block]	'
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented.
	The December 28, 2012 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 28, 2012.
Use of Estimates, Policy [Policy Text Block]	'
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period, Policy [Policy Text Block]	'
	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. The third quarter and year-to-date periods of 2013 and 2012 each contained 13 weeks and 39 weeks, respectively, and ended on September 27, and September 28, respectively.
Income Tax, Policy [Policy Text Block]	'
	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Contingent Liability Reserve Estimate, Policy [Policy Text Block]	'
	In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through Other Operating Expenses, Net. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable milestones.
Long Lived Assets Finite Lived Intangible Assets [Policy Text Block]	'
	The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that it is more likely than not the long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.
	If an indicator is present, potential recoverability is measured by comparing the carrying amount of the long-lived asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group's carrying amount to its fair value
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	'
	The Company assess the impairment of goodwill and other indefinite-lived intangible assets on the last day of each fiscal year, or more frequently if certain indicators are present as described above under long-lived assets. The Company assesses goodwill for impairment by comparing the fair value of its reporting units to their carrying amounts. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	'
	Indefinite-lived intangible assets are assessed for impairment by comparing the fair value of the intangible asset to its carrying value. If the carrying value of the indefinite-lived intangible asset exceeds the fair value, the carrying value is written down to the fair value in the period identified.
Cost And Equity Method Investments Policy [Policy Text Block]	'
	The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments and are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company's investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments.

Acquistions_Tables

Acquistions (Tables)	9 Months Ended
	Sep. 27, 2013
Business Combinations [Abstract]	'
Business Acquisition, Pro Forma Information [Table Text Block]	'
				Three Months Ended				Nine Months Ended
				September 27,		September 28,		September 27,		September 28,
				2013		2012		2013		2012
		Sales		$	167,730	$	161,340	$	487,326	$	487,431
		Net income (loss)			11,071		-7,561		26,486		583
		Earnings (loss) per share:
			Basic	$	0.46	$	-0.32	$	1.11	$	0.02
			Diluted	$	0.44	$	-0.32	$	1.06	$	0.02

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 27, 2013
Supplemental Cash Flow Information [Abstract]	'
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'
					Nine Months Ended
						September 27,		September 28,
		(in thousands)				2013		2012
		Noncash investing and financing activities:
			Common stock contributed to 401(k) Plan		$	2,477	$	4,793
			Property, plant and equipment purchases included
				in accounts payable		711		4,611
		Cash paid during the period for:
			Interest		$	4,388	$	3,250
			Income taxes			31,755		2,923
		Acquisition of noncash assets			$	-	$	14,396
		Liabilities assumed				-		1,244

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 27, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		Inventories are comprised of the following (in thousands):
			As of
				September 27,		December 28,
				2013		2012
		Raw materials	$	67,515	$	58,204
		Work-in-process		38,321		30,022
		Finished goods		16,987		18,386
		Total	$	122,823	$	106,612

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 27, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]	'
		Amortizing intangible assets are comprised of the following (in thousands):
		At	27-Sep-13		Gross Carrying Amount			Accumulated Amortization			Foreign Currency Translation			Net Carrying Amount
		Technology and patents		$	95,576		$	-68,427		$	3,129		$	30,278
		Customer lists			68,257			-22,076			207			46,388
		Other			4,434			-4,385			803			852
		Total amortizing intangible assets		$	168,267		$	-94,888		$	4,139		$	77,518
		At	28-Dec-12
		Technology and patents		$	95,576		$	-61,659		$	1,932		$	35,849
		Customer lists			68,257			-18,929			1,270			50,598
		Other			4,434			-4,341			805			898
		Total amortizing intangible assets		$	168,267		$	-84,929		$	4,007		$	87,345
Schedule of Finite-Lived Intangible Assets, Amortization Expense [Table Text Block]	'
		Aggregate intangible asset amortization expense is comprised of the following (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,			September 28,
			2013			2012			2013			2012
		Cost of sales	$	1,668		$	1,863		$	5,207		$	5,658
		Selling, general and administrative expenses		1,446			1,573			4,343			4,713
		Research, development and engineering costs, net		137			136			409			409
		Total intangible asset amortization expense	$	3,251		$	3,572		$	9,959		$	10,780
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
		Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands):
				Estimated
				Amortization
				Expense
		Remainder of	2013	$	3,207
		2014			13,437
		2015			12,386
		2016			10,092
		2017			8,969
		Thereafter			29,427
		Total estimated amortization expense		$	77,518
Schedule of Intangible Assets Goodwill [Table Text Block]	'
		Indefinite-lived intangible assets are comprised of the following (in thousands):
					Trademarks and Tradenames			IPR&D			Total
		At	28-Dec-12	$	20,288		$	540		$	20,828
		Indefinite-lived asset write-off			-			-426			-426
		At	27-Sep-13	$	20,288		$	114		$	20,402
		The change in goodwill is as follows (in thousands):
					Implantable Medical			Electrochem			Total
		At	28-Dec-12	$	307,201		$	41,834		$	349,035
		Goodwill disposed (Note 9)			-2,771			-			-2,771
		Foreign currency translation			350			-			350
		At	27-Sep-13	$	304,780		$	41,834		$	346,614

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 27, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		Long-term debt is comprised of the following (in thousands):
				As of
					September 27,			December 28,
					2013			2012
		Revolving line of credit		$	10,000		$	33,000
		Variable rate term loan			200,000			-
		2.25% convertible subordinated notes			-			197,782
		Unamortized discount			-			-5,368
			Total long-term debt	$	210,000		$	225,414
Schedule Of Interest Rate Derivatives [Table Text Block]	'
													Current		Fair
											Pay		Receive		Value		Balance
			Type of		Notional			Start		End	Fixed		Floating		Sept. 27,		Sheet
	Instrument		Hedge		Amount			Date		Date	Rate		Rate		2013		Location
	Interest rate swap		Cash flow		$	150,000		13-Feb		16-Feb	0.57%			0.18%	$	-400	Other Long-Term Liabilities
Schedule of Interest [Table Text Block]	'
		The contractual interest and discount amortization for CSN were as follows (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,		September 28,
			2013			2012			2013		2012
		Contractual interest	$	-		$	1,113		$	634	$	3,338
		Discount amortization		-			2,781			5,368		8,205
Schedule Of Maturities Of Long Term Debt [Table Text Block]	'
	The expected future minimum principal payments under the Credit Facility as of September 27, 2013 is as follows (in thousands):
		Remainder of 2013				$	2,500
		2014					10,000
		2015					11,250
		2016					16,250
		2017					20,000
		Thereafter					150,000
		Total				$	210,000
Schedule of Deferred Financing Costs [Table Text Block]	'
		At	28-Dec-12	$	2,056
		Financing costs deferred			2,697
		Write-off during the period			-156
		Amortization during the period			-648
		At	27-Sep-13	$	3,949

Defined_Benefit_Plans_Tables

Defined Benefit Plans (Tables)	9 Months Ended
	Sep. 27, 2013
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	'
		The change in net defined benefit plan liability is as follows (in thousands):
		At	28-Dec-12	$	3,946
		Service cost			227
		Interest cost			144
		Curtailment			-1,581
		Actuarial gain			-171
		Benefit payments			-125
		Foreign currency translation			14
		At	27-Sep-13	$	2,454
Schedule Of Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss [Table Text Block]	'
		Amounts recognized in Accumulated Other Comprehensive Income are as follows (in thousands):
							Nine Months Ended
							27-Sep-13
		Net gain occurring during the period					$	-171
		Amortization of losses						-581
		Prior service cost						155
		Pre-tax adjustment						-597
		Taxes						-
		Net gain					$	-597
Schedule of Net Benefit Costs [Table Text Block]	'
		Net defined benefit cost (income) is comprised of the following (in thousands):
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,		September 28,
			2013			2012			2013		2012
		Service cost	$	76		$	272		$	227	$	835
		Interest cost		41			98			144		305
		Curtailment gain (Other Operating Expenses, Net)		-			-			-1,150		-
		Amortization of net loss		-			30			-		92
		Expected return on plan assets		-			-103			-		-318
		Net defined benefit (income) cost	$	117		$	297		$	-779	$	914

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 27, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		The components and classification of stock-based compensation expense were as follows (in thousands):
			Three Months Ended					Nine Months Ended
			September 27,			September 28,		September 27,		September 28,
				2013			2012		2013		2012
		Stock options	$	1,374		$	671	$	2,784	$	2,038
		Restricted stock and units		2,013			1,523		4,958		4,559
		401(k) stock contribution		679			1,280		3,671		2,410
		Total stock-based compensation expense	$	4,066		$	3,474	$	11,413	$	9,007
		Cost of sales	$	1,117		$	1,119	$	3,246	$	2,486
		Selling, general and administrative		1,598			2,006		6,052		5,732
		Research, development and engineering		215			349		979		789
		2013 operating unit realignment modification expense - Other Operating Expenses, Net (Note 9)		1,136			-		1,136		-
		Total stock-based compensation expense	$	4,066		$	3,474	$	11,413	$	9,007
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		The weighted average fair value and assumptions used to value options granted are as follows:
			Nine Months Ended
				September 27,			September 28,
				2013			2012
		Weighted average fair value	$	8.38		$	8.2
		Risk-free interest rate		0.73%			0.83%
		Expected volatility		39%			40%
		Expected life (in years)		5			5
		Expected dividend yield		0%			0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		The following table summarizes time-vested stock option activity:
							Number of Time-Vested Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value (In Millions)
		Outstanding at			28-Dec-12		1,775,847	$	23.17
			Granted				372,676		23.33
			Exercised				-215,200		22.87
			Forfeited or expired				-69,467		26.2
		Outstanding at			27-Sep-13		1,863,856	$	23.13		6.2	$	19.9
		Exercisable at			27-Sep-13		1,287,345	$	23.17		5	$	13.7
		The following table summarizes performance-vested stock option activity:
							Number of Performance-Vested Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)		Aggregate Intrinsic Value (In Millions)
		Outstanding at			28-Dec-12		284,925	$	23.26
			Granted				0		0
			Exercised				-55,571		23.21
			Forfeited or expired				-		-
		Outstanding at			27-Sep-13		229,354	$	23.27		3.6	$	2.4
		Exercisable at			27-Sep-13		229,354	$	23.27		3.6	$	2.4
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
		The following table summarizes time-vested restricted stock and unit activity:
							Time-Vested Activity		Weighted Average Fair Value
		Nonvested at			28-Dec-12		80,269	$	23.48
			Granted				63,022		25.85
			Vested				-30,592		22.46
			Forfeited				-4,463		21.65
		Nonvested at			27-Sep-13		108,236	$	25.23
		The following table summarizes performance-vested restricted stock and unit activity:
							Performance-Vested Activity		Weighted Average Fair Value
		Nonvested at			28-Dec-12		782,446	$	16.02
			Granted				318,169		15.86
			Vested				-49,139		14.68
			Forfeited				-240,312		14.94
		Nonvested at			27-Sep-13		811,164	$	16.36

Other_Operating_Income_Expense1

Other Operating (Income) Expense (Tables)	9 Months Ended
	Sep. 27, 2013
Other Operating (Income) Expense, Net [Abstract]	'
Schedule Of Other Operating Cost And Expense By Component [Table Text Block]	'
		Other Operating Expenses, Net is comprised of the following (in thousands):
			Three Months Ended				Nine Months Ended
			September 27,		September 28,		September 27,		September 28,
				2013		2012		2013		2012
		2013 operating unit realignment	$	2,214	$	-	$	3,066	$	-
		Orthopaedic facility optimization		1,420		12,452		6,723		14,774
		Medical device facility optimization		52		388		282		1,282
		ERP system upgrade		-121		1,938		264		4,745
		Acquisition and integration (income) costs		-522		232		-340		1,287
		Asset dispositions, severance and other		457		303		565		1,893
			$	3,500	$	15,313	$	10,560	$	23,981
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	'
	The change in accrued liabilities related to the 2013 operating unit realignment is as follows (in thousands):
				Severance and Retention		Other		Total
	At	28-Dec-12	$	0	$	0	$	0
	Restructuring charges			2,153		913		3,066
	Non-cash settlement (modification expense - Note 8)			-1,136		-		-1,136
	Cash payments			-391		-463		-854
	At	27-Sep-13	$	626	$	450	$	1,076
	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands):
			Severance and Retention		Accelerated Depreciation/Asset Write-offs		Other		Total
	At	28-Dec-12	$	9,567	$	-	$	-	$	9,567
	Restructuring charges			544		192		5,987		6,723
	Write-offs			-		-192		-		-192
	Liability assumed by third party			-2,398		-		-		-2,398
	Cash payments			-6,978		-		-5,622		-12,600
	At	27-Sep-13	$	735	$	-	$	365	$	1,100
	The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands):
				Production Inefficiencies, Moving and Revalidation		Personnel		Other		Total
	At	28-Dec-12	$	0	$	0	$	0	$	0
	Restructuring charges			19		2		261		282
	Cash payments			-19		-2		-261		-282
	At	27-Sep-13	$	0	$	0	$	0	$	0
	The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands):
				Training & Consulting Costs		Accelerated Depreciation/ Asset Write-offs		Total
	At	28-Dec-12	$	169	$	0	$	169
	Charges			264		-		264
	Cash payments			-433		0		-433
	At	27-Sep-13	$	0	$	0	$	0

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 27, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Product Warranty Liability [Table Text Block]	'
		At	28-Dec-12	$	2,626
		Additions to warranty reserve			1,372
		Warranty claims paid			-123
		At	27-Sep-13	$	3,875
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
		Remainder of	2013	$	1,400
		2014			5,123
		2015			4,522
		2016			3,826
		2017			1,424
		Thereafter			1,933
		Total estimated operating lease expense		$	18,228
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	'
			Three Months Ended						Nine Months Ended
			September 27,			September 28,			September 27,		September 28,
			2013			2012			2013		2012
		Increase (reduction) in cost of sales	$	-346		$	11		$	-908	$	-8
		Ineffective portion of change in fair value		0			0			0		0
Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]	'
	Instrument		Type of Hedge			Aggregate Notional Amount		Start Date		End Date	$/Peso		Fair Value	Balance Sheet Location
	FX Contract		Cash flow		$	1,500		13-Jan		13-Dec	0.0727	$	59	Current Assets
	FX Contract		Cash flow			1,500		13-Jan		13-Dec	0.0693		138	Current Assets
	FX Contract		Cash flow			7,700		14-Jan		14-Dec	0.0767		-239	Current Assets/ Other Long-Term Liabilities

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 27, 2013
EARNINGS PER SHARE (EPS) [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]	'
	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
				Three Months Ended					Nine Months Ended
				September 27,		September 28,			September 27,		September 28,
				2013		2012			2013		2012
	Numerator for basic and diluted EPS:
		Net income (loss)		$	11,071	$	-7,561		$	26,486	$	757
	Denominator for basic EPS:
		Weighted average shares outstanding			24,047		23,646			23,904		23,559
	Effect of dilutive securities:
		Stock options, restricted stock and restricted stock units			1,141		-			1,113		365
	Denominator for diluted EPS				25,188		23,646			25,017		23,924
	Basic EPS			$	0.46	$	-0.32		$	1.11	$	0.03
	Diluted EPS			$	0.44	$	-0.32		$	1.06	$	0.03
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
					Three Months Ended			Nine Months Ended
					September 27,	September 28,		September 27,		September 28,
					2013	2012		2013		2012
		Time-vested stock options, restricted
			stock and restricted stock units		43,000	2,223,000		59,000		1,237,000
		Performance-vested stock options
			and restricted stock units		27,000	781,000		26,000		692,000

Comprehensive_Income_Tables

Comprehensive Income (Tables)	9 Months Ended
	Sep. 27, 2013
Accumulated Other Comprehensive Income Notes [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	Accumulated Other Comprehensive Income for the quarter and year to date periods are as follows (in thousands):
	Three Month Period		Defined Benefit Plan Liability		Cash Flow Hedges		Foreign Currency Translation Adjustment		Total Pre-Tax Amount		Tax		Net-of-Tax Amount
	At	28-Jun-13	$	-365	$	178	$	10,999	$	10,812	$	338	$	11,150
	Unrealized loss on cash flow hedges			-		-419		-		-419		147		-272
	Realized gain on foreign currency hedges			-		-346		-		-346		121		-225
	Realized loss on interest rate swap hedges			-		145		-		145		-51		94
	Foreign currency translation gain			-		-		3,579		3,579		0		3,579
	At	27-Sep-13	$	-365	$	-442	$	14,578	$	13,771	$	555	$	14,326
	Nine Month Period		Defined Benefit Plan Liability		Cash Flow Hedges		Foreign Currency Translation Adjustment		Total Pre-Tax Amount		Tax		Net-of-Tax Amount
	At	28-Dec-12	$	-962	$	120	$	13,431	$	12,589	$	358	$	12,947
	Unrealized gain on cash flow hedges			-		2		-		2		-1		1
	Realized gain on foreign currency hedges			-		-908		-		-908		318		-590
	Realized loss on interest rate swap hedges			-		344		-		344		-120		224
	Net defined benefit plan gain (Note 7)			597		-		-		597		-		597
	Foreign currency translation gain			-		-		1,147		1,147		-		1,147
	At	27-Sep-13	$	-365	$	-442	$	14,578	$	13,771	$	555	$	14,326

Fair_Value_Tables

Fair Value (Tables)

9 Months Ended

Sep. 27, 2013

Fair Value Disclosures [Abstract]

'

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

'

At

28-Dec-12

$

1,530

Fair value adjustments

-430

At

27-Sep-13

$

1,100

Fair Value, Measurement Inputs, Disclosure [Table Text Block]

'

Fair

Contingent

Value at

Consideration

September 27,

Valuation

Unobservable

Liability

2013

Technique

Inputs

Financial milestones

$

470

Discounted cash flow

Discount rate

12%

Projected year

of payment

2014

Probability weighted payment amount

$

500

Development milestones

630

Discounted cash flow

Discount rate

20%

Projected year

of payment

2016

Probability weighted payment amount

$

1,000

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

'

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheet (in thousands):

Fair Value Measurements Using

Quoted

Prices in

Significant

Active Markets

Other

Significant

At

for Identical

Observable

Unobservable

September 27,

Assets

Inputs

Inputs

Description

2013

(Level 1)

(Level 2)

(Level 3)

Assets

Foreign currency contracts (Note 11)

$

37

$

0

$

37

$

0

Liabilities

Interest rate swap (Note 6)

$

400

$

0

$

400

$

0

Foreign currency contracts (Note 11)

79

0

79

0

Accrued contingent consideration

1,100

0

0

1,100

Business_Segment_Tables

Business Segment (Tables)	9 Months Ended
	Sep. 27, 2013
Geographic Areas, Long-Lived Assets [Abstract]	'
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	'
		Long-lived tangible assets by geographic area are as follows (in thousands):
			As of
				September 27,			December 28,
				2013			2012
		United States	$	117,393		$	123,104
		Rest of world		30,038			27,789
		Total	$	147,431		$	150,893
Geographic Areas, Revenues from External Customers [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
					2013			2012		2013		2012
		Sales by geographic area:
			United States		$	81,736		$	82,522	$	242,304	$	249,306
		Non-Domestic locations:
			Puerto Rico			31,936			31,320		87,592		81,541
			Belgium			14,947			11,346		49,895		41,737
			Rest of world			39,111			36,152		107,535		114,407
				Total sales	$	167,730		$	161,340	$	487,326	$	486,991
Reconciliation from Segment Totals to Consolidated [Abstract]	'
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	'
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
		Sales:			2013			2012		2013		2012
		Implantable Medical
			Cardiac/Neuromodulation		$	86,980		$	80,246	$	242,161	$	235,406
			Orthopaedic			30,079			27,173		92,043		91,079
			Vascular			12,279			13,674		35,152		37,791
				Total Implantable Medical		129,338			121,093		369,356		364,276
		Electrochem
			Portable Medical			19,320			20,219		60,376		59,346
			Energy			13,625			13,054		39,025		41,024
			Other			5,447			6,974		18,569		22,345
				Total Electrochem		38,392			40,247		117,970		122,715
				Total sales	$	167,730		$	161,340	$	487,326	$	486,991
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
					2013			2012		2013		2012
		Segment income from operations:
			Implantable Medical		$	19,074		$	2,744	$	50,057	$	24,252
			Electrochem			2,216			5,350		12,860		16,020
		Total segment income from operations				21,290			8,094		62,917		40,272
		Unallocated operating expenses				-4,288			-5,967		-14,441		-15,856
		Operating income as reported				17,002			2,127		48,476		24,416
		Unallocated other expense				-1,458			-4,299		-10,855		-13,599
		Income (loss) before provision for income taxes			$	15,544		$	-2,172	$	37,621	$	10,817
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		Three customers accounted for a significant portion of the Company’s sales as follows:
					Three Months Ended					Nine Months Ended
					September 27,			September 28,		September 27,		September 28,
					2013			2012		2013		2012
		Customer A				21%			19%		20%		19%
		Customer B				16%			18%		16%		15%
		Customer C				11%			10%		13%		10%
			Total			48%			47%		49%		44%

Basis_of_Presentation_Details

Basis of Presentation (Details)	3 Months Ended		9 Months Ended
	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Basis of Presentation [Abstract]	'	'	'	'
Weeks In Reporting Period	'13	'13	'39	'39

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (Neuro Nexus Technologies Inc [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 16, 2012
Neuro Nexus Technologies Inc [Member]	'
Business Acquisition [Line Items]	'
Business Acquisition, Name of Acquired Entity	'NeuroNexus Technologies, Inc.
Business Acquisition, Description of Acquired Entity	'NeuroNexus is an active implantable medical device design firm specializing in developing and commercializing neural interface technology, components and systems for neuroscience and clinical markets. NeuroNexus has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of neural interface devices across a wide range of applications including neuromodulation, sensing, optical stimulation and targeted drug delivery. The aggregate purchase price of NeuroNexus was $13.2 million. Total assets acquired from NeuroNexus were $14.6 million, of which $2.9 million were amortizing intangible assets and $8.9 million was allocated to goodwill.
Business Acquisition, Cost of Acquired Entity, Cash Paid	$11.70
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	2
Business Acquisition, Contingent Consideration, at Fair Value	$1.50

Acquisitions_Net_Assets_Acquir

Acquisitions (Net Assets Acquired) (Details 1) (Neuro Nexus Technologies Inc [Member], USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 16, 2012
Neuro Nexus Technologies Inc [Member]	'
Business Acquisition [Line Items]	'
Amortizing intangible assets	$2.90
Goodwill	8.9
Total assets acquired	14.6
Net assets acquired	$13.20

Acquisitions_Pro_Forma_Informa

Acquisitions (Pro Forma Information) (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Business Acquisition, Pro Forma Information [Abstract]	'	'	'	'
Sales	$167,730	$161,340	$487,326	$487,431
Net income	$11,071	($7,561)	$26,486	$583
Basic earnings per share	$0.46	($0.32)	$1.11	$0.02
Diluted earnings per share	$0.44	($0.32)	$1.06	$0.02

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]	'	'
Stock Issued During Period, Value, Employee Benefit Plan	$2,477	$4,793
Property, plant and equipment purchases included in accounts payable	711	4,611
Interest Paid	4,388	3,250
Income Taxes Paid	31,755	2,923
Acquisition of noncash assts	0	14,396
Liabilities Assumed	$0	$1,244

Inventories_Details

Inventories (Details) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Inventory Raw Materials	$67,515	$58,204
Inventory, Work in Process	38,321	30,022
Inventory, Finished Goods	16,987	18,386
Inventories	$122,823	$106,612

Intangible_Assets_Amortizing_I

Intangible Assets (Amortizing Intangible Assets) (Details) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$168,267	$168,267
Finite-Lived Intangible Assets, Accumulated Amortization	-94,888	-84,929
Foreign Currency Translation	4,139	4,007
Amortizing intangible assets, net	77,518	87,345
Purchased Technology And Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	95,576	95,576
Finite-Lived Intangible Assets, Accumulated Amortization	-68,427	-61,659
Foreign Currency Translation	3,129	1,932
Amortizing intangible assets, net	30,278	35,849
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	68,257	68,257
Finite-Lived Intangible Assets, Accumulated Amortization	-22,076	-18,929
Foreign Currency Translation	207	1,270
Amortizing intangible assets, net	46,388	50,598
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	4,434	4,434
Finite-Lived Intangible Assets, Accumulated Amortization	-4,385	-4,341
Foreign Currency Translation	803	805
Amortizing intangible assets, net	$852	$898

Intangible_Assets_Amortization

Intangible Assets (Amortization Expense by Categories) (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012	Dec. 28, 2012
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	$3,251	$3,572	$9,959	$10,780	'
Future Amortization Expense, Remainder of Fiscal Year	3,207	'	3,207	'	'
Future Amortization Expense, Year Two	13,437	'	13,437	'	'
Future Amortization Expense, Year Three	12,386	'	12,386	'	'
Future Amortization Expense, Year Four	10,092	'	10,092	'	'
Future Amortization Expense, Year Five	8,969	'	8,969	'	'
Future Amortization Expense, after Year Five	29,427	'	29,427	'	'
Amortizing intangible assets, net	77,518	'	77,518	'	87,345
Cost of Sales [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	1,668	1,863	5,207	5,658	'
Selling General And Administrative Expense [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	1,446	1,573	4,343	4,713	'
Research and Development Expense [Member]	'	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	$137	$136	$409	$409	'

Intangible_Assets_Indefinite_L

Intangible Assets (Indefinite Lived Intangible Assets) (Details 3) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012
Indefinite-lived Intangible Assets [Roll Forward]	'	'
Indefinite-lived intangible assets, beginning	$20,828	'
Impairment Of Intangible Assets Indefinite lived Excluding Goodwill	-426	0
Indefinite-lived intangible assets, ending	20,402	'
Goodwill [Roll Forward]	'	'
Goodwill	349,035	'
Goodwill Disposed	-2,771	'
Goodwill, Translation Adjustments	350	'
Goodwill	346,614	'
Implantable Medical [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill	307,201	'
Goodwill Disposed	-2,771	'
Goodwill, Translation Adjustments	350	'
Goodwill	304,780	'
Electrochem [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill	41,834	'
Goodwill Disposed	0	'
Goodwill, Translation Adjustments	0	'
Goodwill	41,834	'
Trademarks And Tradenames [Member]	'	'
Indefinite-lived Intangible Assets [Roll Forward]	'	'
Indefinite-lived intangible assets, beginning	20,288	'
Impairment Of Intangible Assets Indefinite lived Excluding Goodwill	0	'
Indefinite-lived intangible assets, ending	20,288	'
In Process Research And Development [Member]	'	'
Indefinite-lived Intangible Assets [Roll Forward]	'	'
Indefinite-lived intangible assets, beginning	540	'
Impairment Of Intangible Assets Indefinite lived Excluding Goodwill	-426	'
Indefinite-lived intangible assets, ending	$114	'

Debt_Schedule_of_LongTerm_Debt

Debt (Schedule of Long-Term Debt) (Details) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Line of Credit Facility, Amount Outstanding	$10,000	$33,000
Term Loan	200,000	0
Convertible Subordinated Debt	0	197,782
Debt Instrument, Unamortized Discount	0	5,368
Long-term debt	$210,000	$225,414

Debt_Credit_Facility_Details_D

Debt (Credit Facility Details) (Details 1) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2013
Line of Credit Facility [Abstract]	'
Credit Facility, Amendment Date	20-Sep-13
Line of Credit Facility, Maximum Borrowing Capacity	$300
Term Loan, Maximum Borrowing Capacity	200
Credit Facility Borrowing Capacity Increase	200
Letter of Credit Subfacility Maximum Borrowing Capacity	15
Swingline Subfacility Maximum Borrowing Capacity	15
Line of Credit Facility, Expiration Date	20-Sep-18
Line Of Credit Expiration Date Extension	20-Sep-19
Debt Instrument, Maturity Date	20-Sep-19
DebtInstrumentCollateral	'The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories.
Interest Margin Above Prime Minimum Credit Facility	0.00%
Interest Margin Above Prime Maximum Credit Facility	0.75%
Interest Margin Above LIBOR Minimum Credit Facility	1.38%
Interest Margin Above LIBOR Maximum Credit Facility	2.75%
Interest Margin Above Prime Minimum Swingline	0.00%
Interest Margin Above Prime Maximum Swingline	0.75%
Line of Credit Facility Commitment Fee Percentage Minimum	0.18%
Line of Credit Facility Commitment Fee Percentage Maximum	0.25%
Credit Facility Aggregate Restricted Activities Limit	300
Credit Facility Maximum Permitted Acquisitions	250
Credit Facility Maximum Other Investment Purchases	100
Credit Facility Maximum Stock Repurchases and Declare Dividends	150
Credit Facility Maximum Foreign Subsidiary Investment	20
Leverage Ratio Required To Reset Credit Facility Restrictions	'2.75 to 1.0
Credit Facility Restriction Available	100.00%
Credit Facility Aggregate Restricted Activities Limit Remaining	299
Credit Facility Maximum Oth Investment Purchases Remaining	99
EBITDA Covenant Restriction	'3.0 to 1.0
Total Leverage Covenant Restriction	'4.5 to 1.0
Total Leverage Covenant Restriction 2	'4.25 to 1.0
Total Leverage Covenant Restriction Effective Date	2-Jan-16
DebtInstrumentCovenantCompliance	'As of September 27, 2013, the Company was in compliance with all covenants under the Credit Facility.
DebtWeightedAverageInterestRate	1.81%
DebtInstrumentUnusedBorrowingCapacityAmount	$290

Debt_Convertible_Notes_and_Int

Debt (Convertible Notes and Interest Rate Swap Details) (Details 2) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012	Dec. 28, 2012
Debt Instruments [Abstract]	'	'	'	'	'
Convertible Subordinated Debt	$0	'	$0	'	$197,782,000
Debt Discount Percentage at Issuance	'	'	'	'	5.00%
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	2.25%
Debt Instrument, Interest Rate During Period	'	'	'	'	8.50%
Debt Redemption Date	'	'	20-Feb-13	'	'
Derivative [Line Items]	'	'	'	'	'
Interest expense	1,515,000	4,401,000	9,948,000	13,175,000	'
Interest Rate Swap [Member]	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Type of Hedge	'	'	'Cash flow	'	'
Notional Amount	150,000,000	'	150,000,000	'	'
Start Date	'	'	20-Feb-13	'	'
End Date	'	'	22-Feb-16	'	'
Pay Fixed Interest Rate	0.57%	'	0.57%	'	'
Current Receive Variable Interest Rate	0.18%	'	0.18%	'	'
Annual Notional Amortizing Amount	50,000,000	'	50,000,000	'	'
Description Of Interest Rate Risk Exposure	'	'	'This swap was entered into in order to hedge against potential changes in cash flows on the outstanding Credit Facility borrowings, which are also indexed to the one-month LIBOR rate.	'	'
DescriptionOfInterestRateCashFlowHedgeAccountingMethod	'	'	'This swap is being accounted for as a cash flow hedge.	'	'
Gain (Loss) Recognized In Income Ineffective Portion	0	0	0	0	'
Interest expense	100,000	0	300,000	0	'
Interest Rate Swap [Member] | OtherLiabilitiesMember	'	'	'	'	'
Derivative [Line Items]	'	'	'	'	'
Fair Value	($400,000)	'	($400,000)	'	'

Debt_Contractual_Interest_Deta

Debt (Contractual Interest) (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Interest Costs Incurred [Abstract]	'	'	'	'
Contractual interest	$0	$1,113	$634	$3,338
Discount amortization	$0	$2,781	$5,368	$8,205

Debt_Longterm_Debt_Maturity_Sc

Debt (Long-term Debt Maturity Schedule) (Details 4) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, unless otherwise specified
LongTermDebtByMaturityAbstract	'	'
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	$2,500	'
Long Term Debt Maturities Repayments Of Principal In Year Two	10,000	'
Long Term Debt Maturities Repayments Of Principal In Year Three	11,250	'
Long Term Debt Maturities Repayments Of Principal In Year Four	16,250	'
Long Term Debt Maturities Repayments Of Principal In Year Five	20,000	'
Long Term Debt Maturities Repayments Of Principal After Year Five	150,000	'
Long-term debt	$210,000	$225,414

Debt_Deferred_Financing_Fees_D

Debt (Deferred Financing Fees) (Details 5) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013
Deferred Finance Costs [Roll Forward]	'
Deferred Finance Costs, Net, Beginning Balance	$2,056
Financing Costs Deferred	2,697
Financing Costs Written Off	-156
Amortization Of Financing Costs	-648
Deferred Finance Costs, Net, Ending Balance	$3,949

Defined_Benefit_Plans_Benefit_

Defined Benefit Plans (Benefit Obligation Roll Forward) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]	'	'	'	'
Defined Benefit Plan, Benefit Obligation Beginning	'	'	$3,946	'
Defined Benefit Plan, Service Cost	76	272	227	835
Defined Benefit Plan, Interest Cost	41	98	144	305
Actuarial Gain Loss	'	'	-171	'
Defined Benefit Plan, Benefits Paid	'	'	-125	'
Curtailments	'	'	-1,581	'
Foreign Currency Translation	'	'	14	'
Defined Benefit Plan, Benefit Obligation Ending	$2,454	'	$2,454	'

Defined_Benefit_Plans_Plan_Ass

Defined Benefit Plans (Plan Asset Roll Forward) (Details 1) (USD $)	9 Months Ended
	Sep. 27, 2013
Defined Benefit Plan Change In Fair Value Of Plan Assets [Roll Forward]	'
Defined Benefit Plan, Benefits Paid	($125,000)
Defined Benefit Plan Settlements Plan Assets	$7,700,000

Defined_Benefit_Plans_Amounts_

Defined Benefit Plans (Amounts Recognized in AOCI) (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]	'	'	'	'
Net Gain Loss Arising During Period Before Tax	'	'	($171)	'
Net Gain Loss Recognized In Net Periodic Benefit Cost Before Tax	'	'	-581	'
Prior Service Cost Credit Arising During Period Before Tax	'	'	155	'
Net defined benefit plan liability adjustments	'	'	-597	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax	'	'	0	'
Defined benefit plan liability adjustment, net of tax	$0	$0	($597)	$0

Defined_Benefit_Plans_Defined_

Defined Benefit Plans (Defined Benefit Plan Costs) (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Defined Benefit Plan, Net Periodic Benefit Cost [Abstract]	'	'	'	'
Defined Benefit Plan, Service Cost	$76	$272	$227	$835
Defined Benefit Plan, Interest Cost	41	98	144	305
Net Gain Loss Due To Curtailments	0	0	-1,150	0
Defined Benefit Plan, Amortization of (Gains) Losses	0	30	0	92
Defined Benefit Plan, Expected Return on Plan Assets	0	-103	0	-318
Defined Benefit Plan, Net Periodic Benefit Cost	$117	$297	($779)	$914

Defined_Benefit_Plans_Narrativ

Defined Benefit Plans (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2013
Defined Benefit Plan Disclosure [Line Items]	'
Defined Benefit Plan Settlements Plan Assets	$7.70
Cash And Cash Equivalents [Member]	'
Defined Benefit Plan Disclosure [Line Items]	'
DefinedBenefitPlanWeightedAverageAssetAllocations	100.00%

StockBased_Compensation_Expens

Stock-Based Compensation (Expense Details) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$4,066	$3,474	$11,413	$9,007
Employee Stock Option Member	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	1,374	671	2,784	2,038
Restricted Stock And Unit Awards [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	2,013	1,523	4,958	4,559
Retirement Plan [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	679	1,280	3,671	2,410
Cost of Sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	1,117	1,119	3,246	2,486
Selling General And Administrative Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	1,598	2,006	6,052	5,732
Research and Development Expense [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	215	349	979	789
Other Operating Expenses, net [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$1,136	$0	$1,136	$0

StockBased_Compensation_Fair_V

Stock-Based Compensation (Fair Value Assumptions) (Details 1) (USD $)	9 Months Ended
	Sep. 27, 2013	Sep. 28, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]	'	'
Weighted Average Grant Date Fair Value	$8.38	$8.20
Risk Free Interest Rate	0.73%	0.83%
Expected Volatility Rate	39.00%	40.00%
Expected Term (in years)	'5 years	'5 years
Expected Dividend Rate	0.00%	0.00%

StockBased_Compensation_Stock_

Stock-Based Compensation (Stock Option Activity) (Details 2) (USD $)	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 27, 2013
Stock Options Time Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options Outstanding, Beginning	1,775,847
Option Grants in Period, Gross	372,676
Option Exercises in Period	-215,200
Option Forfeitures and Expirations in Period	-69,467
Stock Options Outstanding, Ending	1,863,856
Options Exercisable, Number	1,287,345
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'
Options Outstanding, Weighted Average Exercise Price, Beginning	$23.17
Option Grants in Period, Weighted Average Exercise Price	$23.33
Option Exercises in Period, Weighted Average Exercise Price	$22.87
Option Forfeitures and Expirations in Period, Weighted Average Exercise Price	$26.20
Options Outstanding, Weighted Average Exercise Price, Ending	$23.13
Options Exercisable, Weighted Average Exercise Price	$23.17
Options Outstanding, Weighted Average Remaining Contractual Term	'6 years 2 months
Options Exercisable, Weighted Average Remaining Contractual Term	'5 years 0 months
Options Outstanding, Intrinsic Value	$19.90
Options Exercisable, Intrinsic Value	13.7
Stock Options Performance Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options Outstanding, Beginning	284,925
Option Grants in Period, Gross	0
Option Exercises in Period	-55,571
Option Forfeitures and Expirations in Period	0
Stock Options Outstanding, Ending	229,354
Options Exercisable, Number	229,354
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'
Options Outstanding, Weighted Average Exercise Price, Beginning	$23.26
Option Grants in Period, Weighted Average Exercise Price	$0
Option Exercises in Period, Weighted Average Exercise Price	$23.21
Option Forfeitures and Expirations in Period, Weighted Average Exercise Price	$0
Options Outstanding, Weighted Average Exercise Price, Ending	$23.27
Options Exercisable, Weighted Average Exercise Price	$23.27
Options Outstanding, Weighted Average Remaining Contractual Term	'3 years 7 months
Options Exercisable, Weighted Average Remaining Contractual Term	'3 years 7 months
Options Outstanding, Intrinsic Value	2.4
Options Exercisable, Intrinsic Value	$2.40

StockBased_Compensation_Stock_1

Stock-Based Compensation (Stock Award Activity) (Details 3) (USD $)	9 Months Ended
	Sep. 27, 2013
Restricted Stock And Restricted Stock Units Time Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'
Nonvested Restricted Stock Units and Awards, Beginning	80,269
Restricted Stock Units and Awards Granted	63,022
Restricted Stock Units and Awards Vested	-30,592
Restricted Stock Units and Awards Forfeited	-4,463
Nonvested Restricted Stock Units and Awards, Ending	108,236
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Beginning	$23.48
Restricted Stock Units and Awards Granted, Weighted Average Fair Value	$25.85
Restricted Stock Units and Awards Vested, Weighted Average Fair Value	$22.46
Restricted Stock Units and Awards Forfeited, Weighted Average Fair Value	$21.65
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Ending	$25.23
Restricted Stock And Restricted Stock Units Performance Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]	'
Nonvested Restricted Stock Units and Awards, Beginning	782,446
Restricted Stock Units and Awards Granted	318,169
Restricted Stock Units and Awards Vested	-49,139
Restricted Stock Units and Awards Forfeited	-240,312
Nonvested Restricted Stock Units and Awards, Ending	811,164
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Beginning	$16.02
Restricted Stock Units and Awards Granted, Weighted Average Fair Value	$15.86
Restricted Stock Units and Awards Vested, Weighted Average Fair Value	$14.68
Restricted Stock Units and Awards Forfeited, Weighted Average Fair Value	$14.94
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Ending	$16.36

Other_Operating_Expense_Net_Ex

Other Operating Expense Net (Expense Categories) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	$3,500	$15,313	$10,560	$23,981
Operating Unit Realignment [Member]	'	'	'	'
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	2,214	0	3,066	0
Orthopaedic Facility Optimization [Member]	'	'	'	'
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	1,420	12,452	6,723	14,774
Medical Device Facility Optimization [Member]	'	'	'	'
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	52	388	282	1,282
ERP System Upgrade [Member]	'	'	'	'
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	-121	1,938	264	4,745
Acquisition And Integration Costs [Member]	'	'	'	'
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	-522	232	-340	1,287
Asset Dispositions Severance And Other [Member]	'	'	'	'
Other Operating Income Expense Detail [Line Items]	'	'	'	'
Other operating (income) expense, net	$457	$303	$565	$1,893

Other_Operating_Expense_Net_Re

Other Operating Expense Net (Restructuring Costs and Reserve Details) (Details) (USD $)

9 Months Ended

3 Months Ended

Sep. 27, 2013

Sep. 28, 2012

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 27, 2013

Sep. 28, 2012

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

Corporate Headquarters Relocation [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Severance And Retention [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Other Restructuring [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Other Restructuring [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Severance And Retention [Member]

Other Restructuring [Member]

Severance And Retention [Member]

Other Restructuring [Member]

Severance And Retention [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Other Restructuring [Member]

Severance And Retention [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Other Restructuring [Member]

Production Inefficiencies, Moving And Revalidation [Member]

Personnel [Member]

Production Inefficiencies, Moving And Revalidation [Member]

Personnel [Member]

Training And Consulting Costs [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Training And Consulting Costs [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Related Activities, Description

'

'

'In June 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its Implantable Medical and Electrochem segments were combined into one sales and marketing and one operations group serving the entire Company.

'

'

'

'

'

'

'In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011.          In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred the manufacturing operations being performed at its Columbia City, IN facility into this new facility. This initiative was completed in 2012. During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, in 2012, the Company entered into an agreement to sell assets related to certain non-core Swiss orthopaedic product lines to an independent third party including inventory, machinery, equipment, customer lists and technology related to these product lines. As these product lines were considered a business, goodwill was allocated to the transaction (See Note 5). As these product lines did not have cash flows that were clearly distinguishable, both operationally and for financial reporting purposes, from the rest of the Company, they were not considered discontinued operations. This transaction closed in the first quarter of 2013 and no additional loss on sale was recognized. During 2013, the Company received payments totaling $3.2 million in connection with this transaction and the third party assumed $2.4 million of severance liabilities.

'

'

'

'

'

'

'

'

'

'

'

'Near the end of 2011, the Company initiated plans to upgrade and expand its manufacturing infrastructure in order to support its medical device strategy. This includes the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives are expected to be completed over the next year.

'

'

'

'

'

'

'

'In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative is expected to be completed over the next six months.

'

'

'

'

'

'

'

Restructuring Initiation Date

'

'

'June 2013

'

'

'

'

'

'

'2010

'

'

'

'

'

'

'

'

'

'

'

'2011

'

'

'

'

'

'

'

'2011

'

'

'

'

'

'

'

Restructuring And Related Activities Expected Capital Expenditures

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000,000

'

'

'

$30,000,000

'

'

'

'

'

$15,000,000

'

'

$20,000,000

'

'

'

$4,500,000

'

'

$5,000,000

'

'

'

Restructuring And Related Activities Capital Expenditures Incurred To Date

'

'

'

'

'

'

'

'

'

22,000,000

'

'

'

'

'

'

'

'

'

'

'

12,400,000

'

'

'

'

'

'

'

4,300,000

'

'

'

'

'

'

'

Restructuring and Related Cost, Expected Cost

'

'

'

6,200,000

5,000,000

1,200,000

7,000,000

5,200,000

1,800,000

'

'

'

'

40,000,000

11,000,000

15,000,000

14,000,000

41,000,000

11,000,000

15,000,000

15,000,000

'

1,000,000

2,000,000

500,000

1,000,000

3,000,000

1,000,000

1,500,000

'

6,000,000

4,000,000

2,000,000

7,000,000

4,500,000

2,500,000

'

Restructuring and Related Cost, Cost Incurred to Date

'

'

3,100,000

'

'

'

'

'

'

39,900,000

'

'

'

'

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

5,300,000

'

'

'

'

'

'

1,200,000

Proceeds from sale of orthopaedic product lines

3,228,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities Assumed By Third Parties

'

'

'

'

'

'

'

'

'

($2,398,000)

($2,398,000)

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other_Operating_Expense_Net_Ch

Other Operating Expense Net Changes in Accrued Liabilities (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013
Operating Unit Realignment [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	$0
Restructuring charges	3,066
Restructuring Reserve, Settled without Cash	-1,136
Cash payments	-854
Restructuring Reserve, Ending Balance	1,076
Orthopaedic Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	9,567
Restructuring charges	6,723
Restructuring Reserve, Settled without Cash	-192
Liability assumed in sale of prouct lines	-2,398
Cash payments	-12,600
Restructuring Reserve, Ending Balance	1,100
Medical Device Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	282
Restructuring Reserve, Settled without Cash	0
Cash payments	-282
Restructuring Reserve, Ending Balance	0
ERP System Upgrade [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	169
Restructuring charges	264
Restructuring Reserve, Settled without Cash	0
Cash payments	-433
Restructuring Reserve, Ending Balance	0
Severance And Retention [Member] | Operating Unit Realignment [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	2,153
Restructuring Reserve, Settled without Cash	-1,136
Cash payments	-391
Restructuring Reserve, Ending Balance	626
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	9,567
Restructuring charges	544
Restructuring Reserve, Settled without Cash	0
Liability assumed in sale of prouct lines	-2,398
Cash payments	-6,978
Restructuring Reserve, Ending Balance	735
Production Inefficiencies, Moving And Revalidation [Member] | Medical Device Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	19
Restructuring Reserve, Settled without Cash	0
Cash payments	-19
Restructuring Reserve, Ending Balance	0
Training And Consulting Costs [Member] | ERP System Upgrade [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	169
Restructuring charges	264
Restructuring Reserve, Settled without Cash	0
Cash payments	-433
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	192
Restructuring Reserve, Settled without Cash	-192
Liability assumed in sale of prouct lines	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | ERP System Upgrade [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Restructuring Reserve, Settled without Cash	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Personnel [Member] | Medical Device Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	2
Restructuring Reserve, Settled without Cash	0
Cash payments	-2
Restructuring Reserve, Ending Balance	0
Other Restructuring [Member] | Operating Unit Realignment [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	913
Restructuring Reserve, Settled without Cash	0
Cash payments	-463
Restructuring Reserve, Ending Balance	450
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	5,987
Restructuring Reserve, Settled without Cash	0
Liability assumed in sale of prouct lines	0
Cash payments	-5,622
Restructuring Reserve, Ending Balance	365
Other Restructuring [Member] | Medical Device Facility Optimization [Member]	'
Restructuring Reserve [Roll Forward]	'
Restructuring Reserve, Beginning Balance	0
Restructuring charges	261
Restructuring Reserve, Settled without Cash	0
Cash payments	-261
Restructuring Reserve, Ending Balance	$0

Income_Taxes_Narratives_Detail

Income Taxes (Narratives) (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2013	Sep. 27, 2013
Income Tax Disclosure [Abstract]	'	'
Unrecognized Tax Benefits	$1.40	$1.40
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1.2	1.2
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0.1	0.1
Convertible Debt Deferred Tax Reclassified To Taxes Payable	30.4	30.4
Tax Payment Related To Convertible Note Deferred Tax	$8	$19.60

Commitments_and_Contingencies_1

Commitments and Contingencies (Narratives) (Details) (USD $)	9 Months Ended
	Sep. 27, 2013
Loss Contingencies [Line Items]	'
Standard Product Warranty Description	'The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Significant Purchase Commitment Description	'Contractual obligations are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum obligations; fixed or minimum price provisions; and the approximate timing of the transaction. The Company’s contractual obligations are normally fulfilled within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable without penalty.
Significant Purchase Commitment Remaining Minimum Amount Committed	$24,100,000
Description of Types of Foreign Currency Cash Flow Hedging Instruments Used	'The Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with the operations at its Tijuana, Mexico facility.
Maximum Aggregate Loss Under Medical Plan Stop Loss Insurance Per Employee	225,000
Accrued Self Insured Medical Plan Liability	$1,900,000
Electrochem Litigation One [Member]	'
Loss Contingencies [Line Items]	'
Loss Contingency Lawsuit Filing Date	'2012
Loss Contingency Domicile Of Litigation	'113th Judicial District Court of Harris County, Texas
Loss Contingency Allegations	'The complaint seeks damages alleging marketing defects and failure to warn, negligence and gross negligence relating to a product Electrochem manufactured and sold to a customer, one of the other named defendants, which, in turn, incorporated the Electrochem product into its own product which it sold to its customer, another named defendant.
Loss Contingency Opinion Of Counsel	'Given the early stages of this action, the amount of loss or range of possible loss cannot be reasonably estimated at this time

Commitments_and_Contingencies_2

Commitments and Contingencies (Product Warranty Rollforward) (Details 1) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013
Movement in Standard Product Warranty Accrual [Roll Forward]	'
Standard Product Warranty Accrual, Beginning Balance	$2,626
Standard Product Warranty Accrual, Warranties Issued	1,372
Standard Product Warranty Accrual, Payments	-123
Standard Product Warranty Accrual, Ending Balance	$3,875

Commitments_and_Contingencies_3

Commitments and Contingencies (Future Lease Payments) (Details 2) (USD $)	Sep. 27, 2013
In Thousands, unless otherwise specified
Operating Leases, Future Minimum Payments Due [Abstract]	'
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	$1,400
Operating Leases, Future Minimum Payments, Due in Two Years	5,123
Operating Leases, Future Minimum Payments, Due in Three Years	4,522
Operating Leases, Future Minimum Payments, Due in Four Years	3,826
Operating Leases, Future Minimum Payments, Due in Five Years	1,424
Operating Leases, Future Minimum Payments, Due Thereafter	1,933
Total estimated operating lease expense	$18,228

Commitments_and_Contingencies_4

Commitments and Contingencies (FX Contract Details) (Details 3) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Foreign Currency Cash Flow Hedges [Abstract]	'	'	'	'
Increase (reduction) in Cost of Sales	($346)	$11	($908)	($8)
Ineffective portion of change in fair value	0	0	0	0
Fx Contract 1 [Member]	'	'	'	'
Derivative [Line Items]	'	'	'	'
Derivative, Type of Instrument	'	'	'FX Contract	'
Notional Amount of Foreign Currency Cash Flow Hedge Derivatives	1,500	'	1,500	'
Start Date	'	'	1-Jan-13	'
End Date	'	'	31-Dec-13	'
$/Peso	0.0727	'	0.0727	'
Fair Value	59	'	59	'
Balance Sheet Location	'	'	'Current Assets	'
Fx Contract 2 [Member]	'	'	'	'
Derivative [Line Items]	'	'	'	'
Derivative, Type of Instrument	'	'	'FX Contract	'
Notional Amount of Foreign Currency Cash Flow Hedge Derivatives	1,500	'	1,500	'
Start Date	'	'	1-Jan-13	'
End Date	'	'	31-Dec-13	'
$/Peso	0.0693	'	0.0693	'
Fair Value	138	'	138	'
Balance Sheet Location	'	'	'Current Assets	'
Fx Contract 3 [Member]	'	'	'	'
Derivative [Line Items]	'	'	'	'
Derivative, Type of Instrument	'	'	'FX Contract	'
Notional Amount of Foreign Currency Cash Flow Hedge Derivatives	7,700	'	7,700	'
Start Date	'	'	1-Jan-14	'
End Date	'	'	31-Dec-14	'
$/Peso	0.0767	'	0.0767	'
Fair Value	($239)	'	($239)	'
Balance Sheet Location	'	'	'Current Assets/ Other Long-Term Liabilities	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]	'	'	'	'
Time-vested stock options, restricted stock and restricted stock units	43,000	2,223,000	59,000	1,237,000
Performance-vested stock options and restricted stock units	27,000	781,000	26,000	692,000
Convertible Note Shares Included In Diluted Share Calculation	0	0	0	0
EARNINGS PER SHARE (EPS) [Abstract]	'	'	'	'
Basic EPS	$0.46	($0.32)	$1.11	$0.03
Diluted EPS	$0.44	($0.32)	$1.06	$0.03
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]	'	'	'	'
Net income (loss)	$11,071	($7,561)	$26,486	$757
Net Income (Loss) Available to Common Stockholders, Diluted	$11,071	($7,561)	$26,486	$757
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]	'	'	'	'
Basic	24,047,000	23,646,000	23,904,000	23,559,000
Effect of dilutive securities convertible subordinated notes	0	0	0	0
Effect of dilutive securities stock optons, restricted stock and restricted stock units	1,141,000	0	1,113,000	365,000
Denominator for diluted EPS	25,188,000	23,646,000	25,017,000	23,924,000

Comprehensive_Income_Details

Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax [Abstract]	'	'	'	'
Cash Flow Hedges, Beginning	$178	'	$120	'
Unrealized gain (loss) on cash flow hedges	-419	'	2	'
Realized Gain Loss On Foreign Currency Contracts Before Tax	-346	'	-908	'
Realized Gain Loss On Interest Rate Swaps Before Tax	145	'	344	'
Cash Flow Hedges, End	-442	'	-442	'
Other Comprehensive Income (Loss), Tax [Abstract]	'	'	'	'
Tax, Beginning	338	'	358	'
Unrealized gain (loss) on cash flow hedges	147	'	-1	'
Realized gain loss on foreign currency contracts - tax	121	'	318	'
Realized gain loss on interest rate swap hedges - tax	-51	'	-120	'
Net defined benefit plan liability adjustments	'	'	0	'
Net foreign currency translation gain (loss)	0	'	0	'
Tax, End	555	'	555	'
Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Period Increase Decrease Abstract	'	'	'	'
Defined Benefit Plan Liability, Beginning	-365	'	-962	'
Net defined benefit plan liability adjustments	'	'	597	'
Defined Benefit Plan Liability, Ending	-365	'	-365	'
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Period Increase Decrease Abstract	'	'	'	'
Foreign Currency Translation Adjustment, Beginning	10,999	'	13,431	'
Net foreign currency translation gain (loss)	3,579	'	1,147	'
Foreign Currency Translation Adjustment, End	14,578	'	14,578	'
Other Comprehensive Income Loss Before Tax Period Increase Decrease Abstract	'	'	'	'
Total Pre-Tax Amount, Beginning	10,812	'	12,589	'
Unrealized gain (loss) on cash flow hedges	-419	'	2	'
Realized gain loss on foreign currency hedges - before tax	-346	'	-908	'
Realized gain loss on interest rate swaps - before tax	145	'	344	'
Net defined benefit plan liability adjustments	'	'	597	'
Net foreign currency translation gain (loss)	3,579	'	1,147	'
Total Pre-Tax Amount, End	13,771	'	13,771	'
Other Comprehensive Income Loss Net Of Tax Period Increase Decrease Abstract	'	'	'	'
Net-of-Tax Amount, Beginning	11,150	'	12,947	'
Unrealized gain (loss) on cash flow hedges, net of tax	-272	'	1	'
Realized gain loss on foreign currency hedges, net of tax	-225	'	-590	'
Realized gain loss on interest rate swap hedges, net of tax	94	'	224	'
Net defined benefit plan liability adjustments	597	'	597	'
Foreign currency translation gain (loss)	3,579	1,005	1,147	-522
Net-of-Tax Amount, End	$14,326	'	$14,326	'

Fair_Value_Measurement_Recurri

Fair Value Measurement (Recurring Measurements) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]	'
Description of Reclassification of Foreign Currency Cash Flow Hedge Gain (Loss)	'The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$0.04

Fair_Value_Measurement_Conting

Fair Value Measurement (Contingent Consideration Roll Forward) (Details 1) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013
Contingent Consideration Liability [Roll Forward]	'
Accrued Contingent Consideration, Beginning Balance	$1,530
Contingent Consideration Recognized In Period	0
Change in Amount of Contingent Consideration Liability	-430
Contingent Payment Related To Business Combination	0
Accrued Contingent Consideration, Ending Balance	$1,100

Fair_Value_Measurement_Conting1

Fair Value Measurement (Contingent Consideration Assumptions) (Details 2) (USD $)	Sep. 27, 2013
In Thousands, unless otherwise specified
Financial Milestones [Member]	'
Fair Value Assumptions [Line Items]	'
Contingent Consideration Fair Value	$470
Risk Adjusted Discount Rate For Contingent Consideration	12.00%
Contingent Consideration Liability Projected Year Of Payment	'2014
Contingent Consideration Liability Probability Weighted Payment Amount	500
Development Milestones [Member]	'
Fair Value Assumptions [Line Items]	'
Contingent Consideration Fair Value	630
Risk Adjusted Discount Rate For Contingent Consideration	20.00%
Contingent Consideration Liability Projected Year Of Payment	'2016
Contingent Consideration Liability Probability Weighted Payment Amount	$1,000

Fair_Value_Measurement_Recurri1

Fair Value Measurement (Recurring Measurement Table) (Details 3) (USD $)	9 Months Ended
	Sep. 27, 2013	Sep. 28, 2012	Dec. 28, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	$37,000	'	'
Foreign Currency Contract Liability Fair Value Disclosure	79,000	'	'
InterestRateDerivativeLiabilitiesAtFairValue	400,000	'	'
Accrued Contingent Consideration	1,100,000	'	1,530,000
Maximum Potential Payment Due Upon Achievement Of Certain Milestones	2,000,000	'	'
Assets, Fair Value Disclosure [Abstract]	'	'	'
Debt Instrument Fair Value	210,000,000	'	'
Long Lived Assets Impairment Loss	0	300,000	'
Impairment Of Intangible Assets Indefinite lived Excluding Goodwill	-426,000	0	'
GoodwillImpairmentLoss	0	0	'
Cost And Equity Method Investments Aggregate Carrying Amount	10,600,000	'	9,100,000
Cost And Equity Method Investments Realized Gains Losses Net	600,000	0	'
Fair Value, Inputs, Level 1 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	'	'
Foreign Currency Contract Liability Fair Value Disclosure	0	'	'
InterestRateDerivativeLiabilitiesAtFairValue	0	'	'
Accrued Contingent Consideration	0	'	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	37,000	'	'
Foreign Currency Contract Liability Fair Value Disclosure	79,000	'	'
InterestRateDerivativeLiabilitiesAtFairValue	400,000	'	'
Accrued Contingent Consideration	0	'	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	'	'
Foreign Currency Contract Liability Fair Value Disclosure	0	'	'
InterestRateDerivativeLiabilitiesAtFairValue	0	'	'
Accrued Contingent Consideration	$1,100,000	'	'

Recovered_Sheet1

Business Segment, Geographic And Concentration Risk Information (Segment Revenue by Categories) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	$167,730	$161,340	$487,326	$486,991
Revenue, Major Customer [Line Items]	'	'	'	'
Revenue Major Customer Percent	48.00%	47.00%	49.00%	44.00%
Customera [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Revenue Major Customer Percent	21.00%	19.00%	20.00%	19.00%
Customer B [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Revenue Major Customer Percent	16.00%	18.00%	16.00%	15.00%
Customer C [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Revenue Major Customer Percent	11.00%	10.00%	13.00%	10.00%
United States [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	81,736	82,522	242,304	249,306
Puerto Rico [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	31,936	31,320	87,592	81,541
Belgium [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	14,947	11,346	49,895	41,737
Rest Of World [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	39,111	36,152	107,535	114,407
Implantable Medical [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	129,338	121,093	369,356	364,276
Implantable Medical [Member] | Cardiac Neuromodulation [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	86,980	80,246	242,161	235,406
Implantable Medical [Member] | Orthopaedic [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	30,079	27,173	92,043	91,079
Implantable Medical [Member] | Vascular [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	12,279	13,674	35,152	37,791
Electrochem [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	38,392	40,247	117,970	122,715
Electrochem [Member] | Portable Medical [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	19,320	20,219	60,376	59,346
Electrochem [Member] | Energy [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	13,625	13,054	39,025	41,024
Electrochem [Member] | Other Electrochem [Member]	'	'	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'	'	'
Sales Revenue, Net	$5,447	$6,974	$18,569	$22,345

Business_Segment_Geographic_An1

Business Segment, Geographic And Concentration Risk Information (Segment Income From Operations) (Details 1) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 27, 2013	Sep. 28, 2012	Sep. 27, 2013	Sep. 28, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Total segment income from operations	$21,290	$8,094	$62,917	$40,272
Unallocated Operating Expenses	-4,288	-5,967	-14,441	-15,856
Operating income as reported	17,002	2,127	48,476	24,416
Unallocated Other Expense	-1,458	-4,299	-10,855	-13,599
Income before provision for income taxes	15,544	-2,172	37,621	10,817
Implantable Medical [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total segment income from operations	19,074	2,744	50,057	24,252
Electrochem [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total segment income from operations	$2,216	$5,350	$12,860	$16,020

Business_Segment_Geographic_An2

Business Segment, Geographic And Concentration Risk Information (Long-lived Assets by Category) (Details 2) (USD $)	Sep. 27, 2013	Dec. 28, 2012
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Property, plant and equipment, net	$147,431	$150,893
United States [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Property, plant and equipment, net	117,393	123,104
Rest Of World [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Property, plant and equipment, net	$30,038	$27,789